# Histopathological growth patterns of liver metastasis: updated consensus guidelines for pattern scoring, perspectives, and recent mechanistic insights.

- 3
- 4 Emily Latacz<sup>1,\*</sup>, Diederik Höppener<sup>2,\*</sup>, Ali Bohlok<sup>3,\*</sup>, Sophia Leduc<sup>4</sup>, Sébastien Tabariès<sup>5</sup>,
- 5 Carlos Fernández Moro<sup>6,7</sup>, Claire Lugassy<sup>8</sup>, Hanna Nyström<sup>9,10</sup>, Béla Bozóky<sup>7</sup>, Giuseppe
- 6 Floris<sup>11,12</sup>, Natalie Geyer<sup>13</sup>, Pnina Brodt<sup>14</sup>, Laura Llado<sup>15</sup>, Laura Van Mileghem<sup>1</sup>, Maxim De
- 7 Schepper<sup>4</sup>, Ali W.Majeed<sup>16</sup>, Anthoula Lazaris<sup>17</sup>, Piet Dirix<sup>1</sup>, Qianni Zhang<sup>18</sup>, Stéphanie K.
- 8 Petrillo<sup>17</sup>, Sophie Vankerckhove<sup>3</sup>, Ines Joye<sup>1</sup>, Yannick Meyer<sup>2</sup>, Alexander Gregorieff<sup>17,19,20</sup>,
- 9 Nuria Ruiz Roig<sup>21,22,23</sup>, Fernando Vidal-Vanaclocha<sup>24</sup>, Larsimont Denis<sup>25</sup>, Rui Caetano
- 10 Oliveira<sup>26,27,28</sup>, Peter Metrakos<sup>17</sup>, Dirk J. Grünhagen<sup>2</sup>, Iris D. Nagtegaal<sup>29</sup>, David G. Mollevi<sup>22,30</sup>,
- 11 William R Jarnagin<sup>31</sup>, Michael I D'Angelica<sup>31</sup>, Andrew R. Reynolds<sup>32</sup>, Michail Doukas<sup>33</sup>,
- 12 Christine Desmedt<sup>4</sup>, Luc Dirix<sup>1</sup>, Vincent Donckier<sup>3,\*</sup>, Peter M. Siegel<sup>5,34,\*</sup>, Raymond
- 13 Barnhill<sup>8,35,\*</sup>, Marco Gerling<sup>13,36,\*</sup>, Cornelis Verhoef<sup>2,\*</sup>, Peter B. Vermeulen<sup>1,\*,⊡</sup>
- 14

15 \*These authors contributed equally

- 17
- <sup>1</sup>Translational Cancer Research Unit (GZA Hospitals, Iridium Netwerk and University of
- 19 Antwerp), Antwerp, Belgium.
- <sup>2</sup>Department of Surgery, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
- <sup>3</sup>Department of surgical oncology, Institut Jules Bordet, Brussels, Belgium.
- <sup>4</sup>Laboratory for Translational Breast Cancer Research, Department of Oncology, KU Leuven,
- 23 Leuven, Belgium.
- <sup>5</sup>Department of Medicine, Rosalind and Morris Goodman Cancer Research Institute, McGill
- 25 University, Montreal, Quebec, Canada.
- <sup>6</sup>Department of Laboratory Medicine, Division of Pathology, Karolinska Institutet, Huddinge,
- 27 Sweden.
- <sup>7</sup>Department of Clinical Pathology and Cancer Diagnostics, Karolinska University Hospital,
- 29 Huddinge, Sweden.
- 30 <sup>8</sup>Department of Translational Research, Institut Curie, Paris, France.
- <sup>9</sup>Department of Surgical and Perioperative Sciences, Surgery, Umeå University, Umeå,
- 32 SWCCE1. This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

- <sup>10</sup>Wallenberg Centre for Molecular Medicine, Umeå University, Umeå, Sweden.
- 34 <sup>11</sup>Department of Imaging and Pathology, Laboratory of Translational Cell & Tissue Research
- 35 and University Hospitals Leuven, KU Leuven, Leuven, Belgium.
- <sup>12</sup>Department of Pathology, University Hospitals Leuven, Campus Gasthuisberg, Leuven,
- 37 Belgium.
- <sup>13</sup>Department of Biosciences and Nutrition, Karolinska Institutet, Huddinge, Sweden.
- <sup>14</sup>Department of Surgery, Oncology and Medicine, McGill University and the Research
- 40 Institute, McGill University Health Center, Montreal, Quebec, Canada.
- 41 <sup>15</sup>HBP and Liver Transplantation Unit, Department of Surgery, Hospital Universitari de
- 42 Bellvitge, IDIBELL, L'Hospitalet de Llobregat, Barcelona, Catalonia, Spain.
- 43 <sup>16</sup>Sheffield Teaching Hospitals NHS Trust, Sheffield, UK.
- 44 <sup>17</sup>Cancer Research Program, McGill University Health Centre Research Institute, Montreal,
- 45 Quebec, Canada.
- 46 <sup>18</sup>School of Electronic Engineering and Computer Science, Queen Mary University of London,
- 47 London, UK.
- <sup>19</sup>Department of Pathology, McGill University, Montreal, Quebec, Canada.
- 49 <sup>20</sup> Regenerative Medicine Network, McGill University, Montreal, Quebec, Canada.
- <sup>21</sup>Department of Pathology, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat,
- 51 Barcelona, Catalonia, Spain.
- 52 <sup>22</sup>Tumoral and Stromal Chemoresistance Group, Oncobell Program, IDIBELL, L'Hospitalet de
- 53 Llobregat, Barcelona, Catalonia, Spain.
- <sup>23</sup>Human Anatomy and Embryology Unit, Department of Pathology and Experimental
- 55 Therapeutics, Faculty of Medicine and Health Sciences, Universitat de Barcelona, Barcelona,
- 56 Catalonia, Spain.
- 57 <sup>24</sup>GWU-Cancer Center, Department of Biochemistry and Molecular Medicine, School of
- 58 Medicine & Health Sciences, The George Washington University, Washington DC, USA.
- <sup>25</sup>Department of Pathology, Institut Jules Bordet, Brussels, Belgium.
- <sup>26</sup>Pathology Department, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal.
- 61 <sup>27</sup>Clinical Academic Center of Coimbra (CACC), Coimbra, Portugal.
- 62 <sup>28</sup>Coimbra Institute for Clinical and Biomedical Research (iCBR) area of Environment Genetics
- and Oncobiology (CIMAGO), Institute of Biophysics, Faculty of Medicine, University of
- 64 Coimbra, Coimbra, Portugal.

- <sup>29</sup>Department of Pathology, Radboud University Medical Center, Nijmegen, Netherlands.
- <sup>30</sup>Program Against Cancer Therapeutic Resistance (ProCURE), Institut Català d'Oncologia,
- 67 L'Hospitalet de Llobregat, Barcelona, Catalonia, Spain.
- 68 <sup>31</sup>Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
- <sup>32</sup>Oncology R&D, AstraZeneca, Cambridge, UK.
- <sup>33</sup>Department of Pathology, Erasmus Medical Center, Rotterdam, The Netherlands
- <sup>34</sup>Departments of Medicine, Biochemistry, Anatomy & Cell Biology, McGill University,
- 72 Montreal, Quebec, Canada.
- 73 <sup>35</sup>Université de Paris l'UFR de Médecine, Paris, France.
- <sup>36</sup>Theme Cancer, Karolinska University Hospital, Solna, Sweden.
- 75

# 76 Funding

- 77 The work by CD, PV, GF, VD, LD, and DL on breast cancer liver metastasis is supported by the
- 78 Foundation against Cancer (Stichting tegen Kanker, Grant C/2020/1441). PV and LD are
- supported by the Koning Boudewijnstichting. GF is a recipient of a post-doctoral mandate
- 80 sponsored by the KOOR from the University Hospitals Leuven. PS is a William Dawson
- 81 Scholar of McGill University and acknowledges funding from the Canadian Institutes of
- 82 Health Research (CIHR: MOP-136907; PJT-175088). HN is supported by the Swedish Research
- 83 Council, Wallenberg Foundations/Knut and Alice Wallenberg Foundation, Region
- 84 Västerbotten, the Swedish Cancer Society, the Cancer Research Foundation in Northern
- 85 Sweden and Umeå University. MG is supported by The Swedish Research Foundation (2018-
- 86 02023) and The Swedish Association for Medical Research. QZ is supported by Engineering
- and Physical Sciences Research Council (project EP/N034708/1). DGM is supported by the
- 88 Fondo de Investigaciones Sanitarias of the Spanish Government, Fondo Europeo de
- 89 Desarrollo Regional (FEDER) "Una manera de hacer Europa" / "A way of shaping Europe"
- 90 (grant PI18/1140) and by AGAUR Department of Health of the Generalitat de Catalunya
- 91 (grant SGR771). WRJ is supported by grant U01 CA238444-02 from the National Cancer
- 92 Institute.93

# 94 Acknowledgement

- 95 The current guidelines are the result of numerous discussions at the annual meetings of the96 international Liver Metastasis Research Network.
- 97

# 98 Conflict of interest

- All authors declare that there are no competing financial interests or other conflicts ofinterest.
- 101

#### 102 Abstract (word count: 191)

103 The first consensus guidelines for scoring the histopathological growth patterns (HGPs) of liver 104 metastases were established in 2017. Since then, numerous studies have applied these guidelines, have further substantiated the potential clinical value of the HGPs in patients with 105 106 liver metastases from various tumour types and are starting to shed light on the biology of the 107 distinct HGPs. In the present guidelines, we give an overview of these studies, discuss novel 108 strategies for predicting the HGPs of liver metastases, such as deep learning algorithms for 109 whole slide histopathology images and medical imaging, and highlight liver metastasis animal 110 models that exhibit features of the different HGPs. Based on a pooled analysis of large cohorts of patients with liver-metastatic colorectal cancer, we propose a new cut-off to categorize 111 112 patients according to the HGPs. An up-to-date standard method for HGP assessment within 113 liver metastases is also presented with the aim of incorporating HGPs into the decision-making 114 processes surrounding the treatment of patients with liver metastatic cancer. Finally, we 115 propose hypotheses on the cellular and molecular mechanisms that drive the biology of the 116 different HGPs, opening some exciting pre-clinical and clinical research perspectives.

#### 118 Introduction

119 The histopathological growth patterns (HGPs) of liver metastases are a morphological 120 reflection of the distinct ways in which cancer cells interact with the surrounding liver. These 121 HGPs can be identified by light microscopy on tissue sections that include the metastasis-liver interface. In 2017, the first set of guidelines for scoring the growth patterns was published<sup>1</sup>. 122 123 Since that time, numerous additional studies have utilized these consensus guidelines to score 124 the HGPs of liver metastases. These studies, listed in Table 1, have further substantiated the 125 clinical value of HGPs in hepatic metastases from colorectal cancer and extended this concept to other tumour types, such as breast carcinoma, melanoma, and pancreatic cancer. 126 127 Moreover, these publications have significantly increased our understanding of HGP biology by describing the molecular and cellular differences between growth patterns by, for example, 128 looking at growth pattern-specific immune responses<sup>2-6</sup>. In addition, attempts have been 129 130 made to develop technologies for predicting HGPs using medical imaging and machine-131 learning algorithms<sup>7-10</sup>. Novel animal models for liver metastasis exhibiting features of the 132 different HGPs are a particularly valuable development<sup>11-17</sup>. These models will allow us to: 1) 133 perform functional validation of HGP-specific signalling pathways described in the clinical 134 samples of liver metastases, 2) identify non-invasive surrogate markers for the different HGPs 135 and 3) test the efficacy of new therapeutic strategies based on the HGPs.

Clinical and experimental studies have provided ample new information that warrants an 136 137 updated, second version of the international guidelines for scoring the HGPs in the context of 138 liver metastasis. The main goal of the guidelines is to incorporate these histological features 139 into the clinical decision-making processes surrounding the treatment of patients with liver 140 metastatic cancer. We therefore provide a detailed histopathological description of the 141 growth patterns of liver metastases and propose an updated standard method for HGP 142 assessment within liver metastases, including immunohistochemical staining as an aid to scoring HGPs. One of the important features of the new guidelines is a modified and clinically 143 144 applicable cut-off for considering a colorectal cancer (CRC) liver metastasis (CRLM) as 145 desmoplastic or non-desmoplastic. This change in cut-off is supported by retrospective studies 146 with large cohorts of patients with liver metastatic CRC<sup>18,19</sup>. In the new guidelines, we present a pooled analysis of previously published cohorts to demonstrate the improved prognostic 147 148 value of this new cut-off recommendation. In addition, we propose hypotheses that could 149 explain the transition from one HGP to another, based on comprehensive immunohistochemical analyses of both the tumour-liver interface and the centre of the
metastases. We also speculate on molecular mechanisms that may underlie the biological
differences of the growth patterns. Finally, we discuss exciting new research perspectives for
the HGPs, including digital image processing techniques and deep learning methods for
automated HGP scoring using digitized haematoxylin-and-eosin-stained (H&E-stained) tissue
sections<sup>20-22</sup>.

#### 158 Methods

#### 159 Literature search

160 We performed a literature search for studies published since January 2015 that focused on the HGPs of liver metastases using the PubMed<sup>R</sup> resource of the U.S. National Library of 161 Medicine. The search terms were designed to find studies on the evaluation of the interface 162 163 between liver metastases and the surrounding liver tissue, independent of the primary 164 tumour type and the host species. Additional studies were found by manual cross-referencing. 165 Ultimately, manuscripts were selected by three reviewers (EL, DJH and PV). Only manuscripts that were not already presented in Table 1 of the first consensus guidelines publication<sup>1</sup> are 166 167 discussed in the current overview table (Table 1).

168

169 Evaluation of the HGP cut-off algorithms

170 To compare the prognostic value of different HGP cut-off algorithms, survival analyses were 171 performed. The HGP and survival data used for these analyses have been previously published 172 as separate cohorts and were pooled for the current analysis<sup>1,18,23-25</sup>. All available H&E-stained 173 sections of all resected liver metastases for every patient included in this assessment were 174 analysed according to the 2017 consensus guidelines<sup>1</sup>. The final HGP score per patient is the 175 average of all metastases, independent of the size of the metastases or number of analysed tissue sections per metastasis. Data on overall and disease-free survival (OS, DFS, defined as 176 177 the time between first liver metastasis resection and death or cancer recurrence, respectively) 178 and HGP were available for 1931 patients: 903 patients underwent surgical resection (1998 -179 2019) in the Erasmus MC Cancer Institute (Rotterdam, the Netherlands), 716 patients in the 180 Memorial Sloan Kettering Cancer Center (New York, NY, USA), and 312 patients in the 181 Radboud University Medical Centre (Nijmegen, the Netherlands). All patients treated with 182 curative intent, who did not receive hepatic arterial infusion pump chemotherapy, and for 183 whom H&E-stained sections were available, were included. Approval by the institutional 184 ethical review boards was obtained in each individual centre separately.

185

#### 186 Immunohistochemistry

For immunohistochemistry with antibodies (clone; manufacturer's code) directed at CK7 (RN7; NCL-L-CK7-560), CK18 (DC-10; NCL-CK18), CK19 (b170; NCL-CK19), CK20 (PW31; NCL-L-CK20-561), Caldesmon (H-CD; Dako-M3557), CD34 (QBEnd/10; Dako-M7165), CD146 190 (UMAB154; Origene-UM800051), NGFR (polyclonal; Atlas-HPA004765) and alpha-SMA (1a4; 191 DAKO-M0851), formalin-fixed paraffin-embedded (FFPE) tissue representing the respective 192 areas were cut to 4 µm thickness. All immunohistochemical stains were done on a Leica 193 (Germany) BOND-MAX automated stainer as part of clinical routine at Karolinska University 194 Hospital, Huddinge, Sweden. Pretreatment was done using Bond Epitope Retrieval Solution 2 195 EDTA (Leica) for 20 minutes. Immunohistochemistry for antibodies directed at melan-A (A103; 196 Dako-M7196) was done on a Leica BOND-RX automated stainer at Institut Curie, Paris, France. 197 Pretreatment was done using Bond Epitope Retrieval Solution 2 EDTA (Leica) for 20 minutes. 198 199 Statistics

For the comparison of different cut-off algorithms, OS and DFS were estimated using the Kaplan-Meier method and reported as 5-year (%), 10-year (%) and median (months) survival including a corresponding 95% confidence interval (CI). Adjusted hazard ratios (HR) for OS and DFS are based on multivariable Cox proportional hazards regression models. All statistical analyses were performed with the R Project for Statistical Computing (version 4.0.2; <u>https://www.r-project.org/</u>).

- 207 Results
- 208 Guidelines

#### 209 Histopathological description of the growth patterns of liver metastases

Liver metastases can interact differently with the liver parenchyma as they colonise the liver, which is manifest histologically as one of several distinct growth patterns. These patterns can generally be identified by light microscopy in H&E-stained sections of FFPE tissue at the interface between the cancer cells and the liver parenchyma<sup>26-30</sup>. The key histopathological characteristics of the HGPs have been described in Table 2 of the first international consensus guidelines<sup>1</sup> and remain valid in that form. An updated overview of the histology of the different HGPs is presented in Table 2 and in Figures 1A-K of the current scoring guidelines.

217 The desmoplastic and the replacement HGPs are the most common patterns, based on recent 218 studies that have used the 2017 consensus guidelines (Table 1). For example, either the 219 desmoplastic or the replacement HGP was evident in 97.5% of the tumour-liver interface of 220 all CRC liver metastases of 732 patients<sup>18</sup>, almost equally distributed between both HGPs. In 221 the desmoplastic HGP, the cancer cells are separated from the surrounding liver parenchyma 222 by a fibrotic rim. Often a dense infiltrate of immune cells is present at the transition between 223 the liver parenchyma and the fibrous rim. Desmoplastic liver metastases frequently show 224 glandular differentiation (when derived from an adenocarcinoma) and are vascularized by a process of angiogenesis<sup>31</sup> (Figures 1A-C). 225

In replacement-type liver metastases, cancer cells are in contact with the hepatocytes, they 226 227 replace the hepatocytes, and, in the process, they co-opt the sinusoidal blood vessels of the 228 liver. As a result, the tissue architecture of the metastases with this HGP mimics the tissue 229 architecture of the liver, such that the metastatic cancer cells arrangement recapitulates 230 'hepatic cell plates' in between co-opted hepatic sinusoidal blood vessels. Typically, and based 231 on observations done in carcinoma liver metastases, only a few immune cells are present at the tumour-liver interface and in the tumour centre<sup>32</sup>, although this is not a scoring criterion. 232 233 Adenocarcinoma metastases with a replacement growth pattern do not usually show 234 glandular differentiation at the tumour-liver interface (Figures 1D-F). Angiotropic 235 extravascular migration has been observed in replacement-type liver metastases of melanoma<sup>33</sup> (see section dedicated to angiotropic extravascular migration): single or small 236 237 clusters of melanoma cells may extend along sinusoidal channels into the surrounding liver 238 parenchyma with distances of several millimeters.

239 The pushing growth pattern is an uncommon pattern. For example, the pushing HGP was 240 present in only 2.5% of the tumour-liver interface of all CRC liver metastases of 732 patients<sup>18</sup>. This growth pattern is characterized by cancer cells that appear to push away the liver 241 242 parenchyma without an intervening fibrous rim. Cancer cells do not invade the hepatocyte 243 plates, they do not replace the hepatocytes, and they do not co-opt the sinusoidal blood 244 vessels. The surrounding liver is composed of hepatocytes that are arranged parallel to the 245 tumour-liver interface and appear slender because they are atrophic or compressed by the 246 growing metastases (Figures 1G and 1H).

247 Liver metastases with a sinusoidal HGP are characterized by cancer cells that fill the sinusoidal 248 vascular spaces (Figure 1I). The sinusoidal HGP appears limited to patients with aggressive 249 disease and is more frequently encountered in autopsy specimens, which could imply that it is a feature of end-stage disease <sup>7,34-37</sup>. Liver metastases can also spread along the portal 250 251 tracts. Cancer cells can invade the fibrous stroma of these tracts, fill the lumen of portal vein 252 branches or the lymphatic vessels, or grow along nerves (neurotropism) and blood vessels 253 (angiotropism). In addition, cancer cells can proliferate inside biliary ducts of the portal tracts 254 by replacing the normal epithelial lining of these ducts (Figures 1J and 1K).

255 Tumour type-dependent differences in the growth patterns have been described. For 256 example, when comparing the replacement HGP in breast cancer metastases and CRLM, the 257 histological characteristics of replacement growth were often present from the tumour-liver 258 interface and up to the centre of the metastases in the breast cancer cases, while they were limited to the interface in all CRLM<sup>38</sup>. Also, the presence of single cancer cells in the liver 259 260 parenchyma at a distance from the tumour-liver interface in replacement-type liver 261 metastases (so called angiotropic extravascular migration) appears to be more obvious in 262 melanoma liver metastases than in liver metastases of CRC or other carcinomas (unpublished 263 observations).

264

# 265 Update of the cut-off value to categorize patients with colorectal cancer according to the 266 histopathological growth pattern of the liver metastases

Given that a single liver metastasis can be composed of regions with different growth patterns,
this histological parameter is assessed by estimating the relative fraction of the total length of
the interface for each growth pattern present in the metastasis. In cases of multiple sections
per metastasis or multiple liver metastases per patient, the mean percentage across sections

and lesions, respectively, is calculated<sup>1</sup>. In the previous version of the scoring guidelines, a 50% cut-off was proposed to categorize patients, based on its prognostic value. This approach generated four distinct HGP classes: 'predominant desmoplastic', 'predominant replacement', 'predominant pushing' and a 'mixed' class in the absence of a predominant HGP. Multiple studies have demonstrated a favourable outcome in patients with CRC liver metastases with a predominant desmoplastic HGP (Table 1).

277 However, the results of a study by Galjart and colleagues from the Erasmus Medical Centre in Rotterdam<sup>18</sup> provide a strong rationale for revising the cut-off value used to clinically 278 279 categorize patients with CRC liver metastases according to the HGP. The study compared 280 different cut-offs based on a large dataset of patients with CRLM. The results suggest that the 281 prognosis of patients with resected CRC liver metastases is primarily determined by the 282 presence of a replacement and/or a pushing growth pattern as opposed to a pure 283 desmoplastic growth pattern (corresponding to 100% of the assessed tumour-liver interface). 284 Favourable survival rates were demonstrated only for patients with liver metastases with 285 complete desmoplastic growth, a condition present in 24% of all patients included in the study by Galjart et al (2019)<sup>18</sup>. Remarkably, non-desmoplastic growth - of any fraction - reduced the 286 287 5-year OS rate from 78% to 37% in the cohort of patients who did not receive pre-surgery 288 systemic treatment (adjusted HR 0.39; 95% CI: 0.23-0.67) and from 53% to 40% in the cohort 289 of patients who did receive pre-surgery systemic treatment (adjusted HR 0.92; 95% CI: 0.64-290 1.30). This difference in outcome was recently confirmed in a large multicentre external validation study<sup>19</sup>. 291

292 We now present a comprehensive clinical evaluation of a large international multicentre 293 cohort of 1931 patients with CRC in which we assessed the impact on outcome using the recent 'Rotterdam cut-off'<sup>18,19</sup> compared to the 'predominant HGP cut-off' described in the 294 295 original international consensus guidelines<sup>1</sup>. The clinicopathological baseline and treatment 296 characteristics are summarized in Table 3. The median follow-up for survivors was 67 months 297 (interquartile range: 34 – 112 months). When applying the Rotterdam cut-off, 1516 (79%) 298 patients had non-desmoplastic liver metastases and 21% had pure desmoplastic liver 299 metastases. Of the 1516 patients with a non-desmoplastic HGP, 201 (10%), 549 (28%), 305 300 (16%), and 461 (24%) patients had liver metastases with a 100%, 67.1-99%, 33.1-67%, and 0.1-301 33% non-desmoplastic HGP, respectively (Table 4). When patients were classified according 302 to the predominant HGP cut-off, 839 (43%) patients had liver metastases with a predominant

replacement HGP, 19 (1%) with a predominant pushing HGP, 1031 (53%) with a predominant
desmoplastic HGP, and 42 (2%) with a mixed HGP (Table 4). The following findings support the
'Rotterdam cut-off':

 Patients with resected CRC liver metastases that possess an exclusively desmoplastic growth pattern have a clear survival advantage over all other patients. Median OS (months (95% CI)) for desmoplastic versus non-desmoplastic patient cohorts is 88 (77-112) versus 53 (49-58) months, respectively. Median DFS for desmoplastic versus nondesmoplastic patient cohorts is 24 (20-33) versus 11 (11-12) months, respectively (Figures 2A and 2B, Table 4). The adjusted HRs for OS and DFS (95% CI) are 0.64 (0.52-0.78) and 0.61 (0.52-0.71), respectively (Table 4).

2. There is no difference in survival among patients belonging to the discrete non-313 314 desmoplastic classes (Figures 2C and 2D, Table 4). This probably explains why the 315 survival advantage of the favourable patient cohort over the unfavourable patient cohort is less pronounced when the predominant HGP cut-off algorithm is used 316 317 (Figures 2E and 2F, Table 4). For example, the adjusted HR for OS is 0.64 (95% CI: 0.52-318 0.78) versus 0.76 (95% CI: 0.65-0.88) respectively, when comparing the Rotterdam and 319 the 'predominant HGP' cut-offs (Table 4). A similar difference of 0.61 (95% CI: 0.52-320 0.71) versus 0.82 (95% CI: 0.73-0.93) can be observed for DFS (Table 4).

3. The learnability and accuracy of HGP-scoring according to the new cut-off have been 321 shown to be high<sup>39</sup>. Moreover, this algorithm represents a simplified method of HGP 322 scoring when considering prognostic impact. Indeed, when a non-desmoplastic 323 324 component (replacement or pushing) is detected while analysing a series of H&E-325 stained sections from a patient, the result is clear, and no further scoring is required. However, for scientific research purposes, and to further validate the new cut-off 326 327 approach, care should be taken not to compromise the acquisition of more detailed 328 quantitative data and assessing the HGPs in all the available H&E-stained sections of 329 all the resected liver metastases is still preferred.

The international group of authors of this second consensus guidelines for scoring HGPs of hepatic metastases therefore proposes to test this algorithm in prognostic studies with other primary tumour types as well. In studies that aim at deciphering the molecular underpinnings of the different growth patterns, a cut-off agnostic approach should probably be adopted, to not obscure lessons to be learned from inter-tumour heterogeneity of the HGPs.

335

#### 336 Categorization of the histopathological growth patterns of non-CRC liver metastases

337 Distinct HGPs have been identified in liver metastases from a broad range of primary solid 338 tumours, mostly carcinomas. The replacement (also referred to sometimes as 'replacing', 339 'trabecular' or 'infiltrative') growth pattern, the desmoplastic growth pattern (also sometimes 340 called 'encapsulated') and the pushing growth pattern (also sometimes called 'expansive') 341 have been described in liver metastases from primary lung, pancreatic, stomach, gallbladder/bile duct and breast carcinoma<sup>5,38,40-42</sup>. The study of HGPs in liver metastases from 342 343 these tumour types is relevant given that, for example, about 11% of patients with lung 344 carcinomas, 36% of patients with pancreatic carcinoma and 14% of patients with stomach cancer have liver metastases at diagnosis<sup>43</sup>. The sinusoidal growth pattern has been 345 346 encountered in autopsy specimens of patients with non-small cell lung cancer (NSCLC) and breast cancer<sup>7,34-37</sup>. In addition to carcinomas, the desmoplastic, pushing, replacement and 347 348 sinusoidal growth patterns have also been identified in hepatic metastases of both skin and 349 uveal melanoma<sup>44-46</sup>. Additional types of HGP have also been described in uveal melanoma, 350 however without evaluation of the interface between liver metastases and the surrounding 351 liver tissue<sup>46,47</sup>. In these studies, the different results reported may be ascribed to the sources 352 of material studied, almost entirely derived from autopsies, and of partial biopsy samplings. 353 The HGPs have recently also been identified in sarcoma-derived hepatic metastases, in a study 354 describing the HGPs in a cohort of patients with non-colorectal, non-neuroendocrine liver metastases<sup>48</sup>. 355

356 Although the prognostic/predictive role of the HGPs has been studied mainly in patients with CRC<sup>1,18,19,49</sup>, there are recent reports on the impact of the HGPs on outcome in patients with 357 358 liver metastatic melanoma, breast carcinoma and pancreatic cancer<sup>5,42,44,45</sup>. In a study of 42 359 patients with skin melanoma, the presence of any replacement HGP (1% of the tumour-liver 360 interface or more), present in 20 patients (48%), significantly predicted worse overall survival 361 while the 100% desmoplastic HGP correlated with improved OS, an effect that continued to 362 be significant upon multivariate analysis (HR = 3.79, p = 0.01)<sup>45</sup>. In a study of 41 patients with 363 liver metastatic uveal melanoma, the dominant HGP (>50% of tumour-liver interface) was used to categorize patients<sup>44</sup>. A dominant replacement HGP, present in 30 patients (73%), 364 365 predicted diminished OS with a HR in multivariate analysis of 6.51 (p = 0.008). An updated 366 analysis with extension of the patient cohort and categorisation according to the 100%

367 desmoplastic HGP cut-off has recently been completed (Barnhill et al, manuscript in368 preparation).

369 The HGPs of breast cancer liver metastases have only been sporadically studied and have been mainly described in autopsy specimens<sup>34,35,38,41</sup>. In this context, and when compared with CRC 370 liver metastases, the replacement HGP and even the sinusoidal HGP are more frequently 371 372 encountered in breast cancer liver metastases. Surgical removal of breast cancer hepatic 373 metastases is still rarely practiced. However, there is a subpopulation of patients with liver 374 metastatic breast carcinoma for whom a favourable course after resection has been documented, contradicting the common idea that breast cancer is always a systemic disease<sup>50</sup> 375 376 and a rationale behind ongoing clinical trials, for example BreCLIM-2 (ClinicalTrials.gov Identifier: NCT04079049). With this in mind, Bohlok et al (2020)<sup>42</sup> have scored the HGPs in 36 377 378 patients who underwent surgical resection for breast cancer liver metastases. Given that only 379 one patient presented with liver metastases with a pure desmoplastic HGP while 16 patients 380 had liver metastases with a pure replacement HGP, a pragmatic approach was adopted to 381 categorize patients as having liver metastases with '100% replacement' versus 'any 382 desmoplastic' HGP. The study confirmed the association of replacement HGP liver metastases 383 with poor outcome as observed with other tumour types. Indeed, all patients with a pure 384 replacement HGP relapsed within 2 years after surgery. In addition, even in this small cohort of patients, improved OS was observed for patients with 'any desmoplastic' HGP liver 385 386 metastases as compared to the other patients upon multivariate analysis (HR = 0.20, p = 0.023)<sup>42</sup>. A large international study has recently been undertaken by several authors of the 387 388 guidelines to further address the impact of the HGPs on outcome in patients with liver 389 metastatic breast cancer.

More than one-third of patients with neuroendocrine tumours (NETs) present with distant disease, with the liver being the most common metastatic site. Although newer therapeutic options are becoming available, resection of NET liver metastases is still often performed<sup>51</sup>. Given the broad spectrum of NETs, from well-differentiated NETs to poorly differentiated neuroendocrine carcinomas, it would be interesting to study the HGPs of NET liver metastases. To the best of our knowledge, this has not been done yet.

396 In conclusion, the distinct HGPs can be identified independently of the primary solid tumour 397 type and the desmoplastic HGP is invariably associated with better outcome than the 398 replacement HGP, after surgical removal of liver metastases. This is consistent with the idea

399 that common, tumour type-independent and liver-specific biological programs are activated

400 in liver-metastatic cancer cells and shape growth pattern emergence in the liver<sup>52</sup>.

401

# 402 Clinical significance of the pushing growth pattern

403 The prognostic/predictive value of the pushing HGP is still unclear. Before the first 404 international guidelines were published, there were no unequivocal instructions for 405 distinguishing the pushing HGP from the replacement HGP where tumour cells appear to push 406 away the liver parenchyma (so called pushing-type or type-2 replacement HGP)<sup>1</sup>. As a result, 407 the proportion of metastases with a pushing HGP has been overestimated in studies carried out prior to the publication of the first consensus guidelines<sup>49</sup>. For example, Nielsen et al. 408 (2014)<sup>53</sup> and Eefsen et al. (2015)<sup>54</sup> reported that 45% of the patients with resected CRC liver 409 410 metastases presented with a dominant pushing HGP. By applying the consensus guidelines of 411 2017, the proportion of metastases with a pushing HGP was found to be reproducibly smaller 412 across more recent studies. In the study by Galjart et al. of 2019<sup>18</sup>, for example, less than 1% 413 of patients presented with a dominant pushing HGP in their CRC liver metastases. Determining 414 the clinical value of the pushing HGP will therefore only be possible in large multi-centre 415 studies.

416

#### 417 The histopathological growth patterns and treatment response

418 Several observations suggest that systemic treatment can alter the HGP of liver metastases. In the study by Frentzas et al. (2016)<sup>41</sup>, the growth pattern of recurrent CRLM, defined as those 419 420 metastases that were not detectable by imaging before systemic treatment but appeared 421 during bevacizumab-chemotherapy, was compared with the growth pattern of metastases 422 that were already visible before systemic treatment. The recurrent metastases more often 423 demonstrated a replacement HGP when compared to the metastases that were already visible 424 before systemic treatment (80% versus 50%). In support of these observations, several 425 preclinical studies have demonstrated the switch from an angiogenic to a vessel co-opting 426 growth pattern associated with resistance to treatment with anti-VEGF drugs in several 427 malignancies. These include hepatocellular carcinoma<sup>55</sup>, lung metastases of renal cell carcinoma<sup>56</sup>, brain metastases of melanoma<sup>57</sup> and glioblastoma<sup>58</sup>. 428

Other studies<sup>59,60</sup> found associations between systemic treatment of patients with CRLM and
 histological characteristics that are highly suggestive of replacement growth. The so-called

431 'dangerous halo' consists of an irregular tumour-liver interface in a CRLM that was seen 432 selectively in patients that received chemotherapy before partial hepatectomy. Although 433 beyond the scope of the Mentha et al. study, the histological images in their report show that 434 the 'dangerous halo' consists of areas of replacement growth while the lesion without the 'dangerous halo' has a desmoplastic HGP (Figure 1 in Mentha et al. (2009)<sup>59</sup>). Taken together, 435 the findings of Frentzas et al. (2016)<sup>41</sup> and the reports on the 'dangerous halo'<sup>59,60</sup> link the 436 437 replacement HGP to chemotherapy resistance with or without anti-VEGF treatment in 438 patients with liver metastatic colorectal cancer.

439 There are, however, studies suggesting that chemotherapy induces the desmoplastic growth pattern in patients with replacement-type CRLM<sup>18,61</sup>. Nierop and colleagues (2021)<sup>61</sup> have 440 assessed the HGP of resected liver metastases in three cohorts of respectively 877, 1203 and 441 442 70 patients with CRC, respectively. The latter cohort was derived from a phase III clinical trial in which patients were randomized between either peri-operative chemotherapy and 443 444 resection or resection only. In all three cohorts, the average presence of the desmoplastic HGP 445 at the tumour-liver interface was significantly higher in patients with pre-operative 446 chemotherapy compared to chemo-naïve patients (67% versus 43%, 63% versus 40%, and 61% versus 33%, respectively (p<0.005)). The fact that this shift in HGP was observed in a 447 448 randomised study is consistent with a lack of selection in the association of pre-operative 449 chemotherapy and the desmoplastic HGP. However, it remains to be determined whether 450 chemotherapy induces a transformation of replacement-type liver metastases into lesions 451 that form a desmoplastic rim or whether pre-existing desmoplastic lesions are more resistant 452 to chemotherapy.

453 Taken together, it appears that a transition from one HGP to another could occur in patients 454 with CRLM following systemic treatment. However, despite all the studies discussed above, a 455 reliable assessment in individual patients of the effect of systemic treatment on the HGPs of 456 liver metastases will only be possible when non-invasive imaging (as discussed below) or blood 457 analyses will be available to identify the HGPs at several time points during treatment. One 458 promising blood marker was recently proposed<sup>16</sup>. Circulating extracellular vesicles (EVs) 459 derived from patients with replacement-type CRLM exhibited significantly higher protein 460 expression of Claudin-2 relative to EVs isolated from patients with desmoplastic liver 461 metastases. Thus, high protein levels of Claudin-2 in EVs isolated in the blood circulation of 462 patients with liver metastatic CRC may predict the replacement HGP in CRLM.

#### 463

# 464 Standard method for assessment of the histopathological growth patterns of liver 465 metastases

466 The updated consensus guidelines for tissue sampling of surgical liver resections and for scoring and reporting of the HGPs of liver metastases are presented in Table 5. The proposed 467 468 sampling guidelines are not based on published experimental evidence but are rather an 469 empirical approach<sup>62</sup>. Given that the invasion front of liver metastases is often heterogeneous 470 in respect to HGPs, a balance must be struck between accurate assessment of growth patterns 471 and practical feasibility of sampling in a pathology laboratory. In addition, the sampling 472 procedure may be tumour-type dependent. For example, when dealing with CRLM, a two-473 step approach can be envisaged for clinical routine, given that the presence of any proportion 474 of the interface with a non-desmoplastic HGP in any of the resected metastases has clear prognostic significance<sup>18,19</sup>. Initial sampling or scoring may consist of a limited number of 475 476 paraffin blocks and in the event that a region with a non-desmoplastic growth is identified in 477 the H&E-stained sections, the patient will be categorized into the corresponding HGP group. 478 In accordance with our proposed updated guidelines, additional and more extensive sampling 479 or scoring will only be necessary if no regions with non-desmoplastic growth are encountered 480 at initial sampling or scoring.

481 In reporting the HGPs of liver metastases, several factors will need to be considered. The 482 context of HGP assessment and the primary tumour type need to be considered because they 483 will determine how a patient will be categorised based on the liver metastasis HGP. For 484 example, for patients with CRLM, the HGP can provide prognostic information. For these 485 patients, categorization can, therefore, be based on the cut-off specified in the current 486 guidelines. For other primary tumour types, large studies that have defined a clinically 487 relevant cut-off value are still lacking and data reporting should be as precise as possible, in 488 order for the HGP-score to be available for future data analyses because predictive and 489 prognostic HGP cut-off values may be different for different primary tumour types.

There are essentially two ways to report HGPs when multiple metastases are resected. One approach simply averages the scores for each HGP (desmoplastic, replacement, pushing) across every available H&E-stained section for all the resected metastases. The other approach uses an average of the scores for each HGP of all the available H&E-stained sections for each individual metastasis separately and reports a score for every metastasis that has 495 been resected. The latter approach may be used when biological differences between
496 metastases are expected, for example related to a difference in response to pre-surgery
497 systemic treatment.

498 With the aim of identifying the presumed treatment-induced transition towards the 499 replacement HGP in future studies, we propose the following clinicopathological definition of 500 an 'escape' phenotype: 'Liver metastases resected after pre-operative systemic treatment 501 combining signs of pathological response in the centre of the metastases while also exhibiting 502 at least a partly preserved desmoplastic rim and small peripheral areas of replacement-type 503 outgrowth or a complete halo of replacement growth'. Typically, these areas of replacement 504 growth do not show any of the characteristic signs of treatment response, as shown in 505 examples in Figure 3. Further information on the clinical value of this phenotype and its 506 biological underpinning will be derived from future studies on the HGPs of liver metastases. 507 We therefore propose to score the presence or absence of 'escape' in liver metastases that 508 are resected after administration of systemic pre-operative treatment.

509

#### 510 Immunohistochemical staining as an aid to scoring HGPs

511 In some liver metastases, the histology is more complex, and this can result in a less 512 straightforward assessment of the HGPs. The 'caveats' are listed in the Table 5. Although the 513 assessment of HGPs of liver metastases is based exclusively on H&E-stained tissue sections, 514 additional immunohistochemical analyses may provide clarity when these challenging 515 conditions arise.

516 One example is the presence of an extensive immune cell infiltrate that obscures the tumour-517 liver interface. In this case, the presence or absence of contact between tumour cells and 518 hepatocytes and the degree of hepatocyte co-option will determine whether the replacement 519 HGP must be considered. A double immunostaining approach coupling a hepatocyte marker and a tumour cell marker can also be useful in such cases. For example, for liver metastases 520 521 from a colorectal carcinoma, the combination of antibodies directed against caudal type 522 homeobox 2 (CDX-2), cytokeratin (CK) 20 or CK19 (tumour cells) and Hepar-1, arginase1, or 523 CK18 (hepatocytes) can be used (Figure 4A). This immunostaining may also help to distinguish 524 a replacement HGP in which the liver cell plates are pushed away from the rare pushing HGP 525 (Figure 4B).

526 A second example where a clear-cut assessment of the HGP may be challenging is the 527 presence of a prominent ductular reaction at the tumour-liver interface. It can indeed be 528 difficult to distinguish cancer cells from cholangiocytes in this ductular reaction, especially 529 when nuclear pleomorphism of the cancer cells is limited and small aggregates or glandular 530 structures of cancer cells are formed. In addition, cancer cells and cholangiocytes can be 531 involved in common ductular structures. A possible solution is to combine cholangiocyte (CK7, 532 CK19 or carbohydrate antigen 19-9 (CA19-9)) and cancer cell markers (for CRLM, for example 533 CK20 or CDX-2) (Figure 4C) as an added tool for the analysis. Double immunostaining for 534 cancer cell and cholangiocyte markers can also be used to identify intrabiliary growth when 535 only a few cholangiocytes remain that are difficult to detect on an H&E-stained section (Figure 536 4D).

- 537
- 538

539 Perspectives

#### 540 Patient-derived xenograft models to study the HGPs of liver metastases

The characterization of the distinct growth patterns using protein-based and genomic approaches on surgically resected clinical specimens has begun to shed light on the underlying biological processes that might drive the formation and growth of these lesions (Table 1). However, the field currently lacks animal models that faithfully recapitulate the specific histological features of these metastases (in particular desmoplastic metastases), necessary for functional dissection of the molecular mediators that are currently only associated with one type of lesion or the other.

548 To better understand the underlying biology of desmoplastic and replacement liver 549 metastases and to test therapeutic strategies tailored to these distinct lesions, it will be 550 important to develop PDXs that faithfully recapitulate the histological features seen in 551 patients. To this end, members of the Liver Metastasis Research Network at the Goodman 552 Cancer Institute (McGill University) and the McGill University Health Centre have developed a 553 patient-derived xenograft (PDX) pipeline where freshly resected CRLM, or biopsy samples, 554 from the operating theatre are brought immediately to the laboratory and are directly implanted into the livers of SCID/beige mice<sup>16</sup>. The surgical specimen is divided into 555 556 approximately 1mm<sup>3</sup> fragments, which are then carefully inserted into an incision made in the 557 left cardiac liver lobe of recipient mice. This approach has led to the successful establishment 558 of more than 30 PDX models that represent both replacement and desmoplastic lesions. 559 Importantly, a high degree of concordance (over 95%) between the HGPs of the metastases 560 that develop in the PDX models, when compared to the metastatic lesion in the patients from 561 which they were derived, has been achieved. In addition, organoids from these PDX models 562 have been generated (PDXOs) and propagated in culture (Tabariès S, Gregorieff A and Siegel 563 P, unpublished observations). When re-injected into the livers of mice, these PDXOs generate 564 desmoplastic or replacement lesions that recapitulate the HGP of the patient sample and PDX 565 model (Figure 5). While these models may provide useful information on the drivers 566 underlying specific HGPs, the lack of an adaptive immune response in the recipient mice, may 567 present a challenge to obtaining complete information on the associated immune 568 microenvironments. Although several methods have been described to generate so-called 569 'humanised mice', a less challenging approach is represented by the patient-derived explants 570 (PDE), ex vivo systems in which the in vivo tissue architecture and immune microenvironment 571 of human tumours can be maintained<sup>63</sup>. These PDE platforms have been shown to be able to 572 predict clinical response to inhibitors of the PD-1-PD-L1 axis in patients with various types of cancer<sup>64</sup> and might thus be used to study the biology of liver metastases with distinct HGPs. 573

- 574
- 575

### 576 Automated scoring of HGPs of liver metastasis

577 An increasing number of pathology laboratories are digitising glass slides into high-resolution 578 whole slide images (WSIs). This creates an opportunity to develop algorithms based on 579 machine learning and artificial intelligence that can extract clinically useful information from, 580 for example, WSIs of H&E-stained tumour sections. At least two teams have implemented this 581 approach to score the HGPs of liver metastases in an automated way.

582 The algorithm developed by Qianni Zhang and her team determines the relative contribution 583 of the replacement and of the desmoplastic HGP in a CRC liver metastasis, including the 584 proportion of the tumour-liver interface with 'uncertain' HGP<sup>20</sup>. By combining image 585 processing and deep learning methods, they can achieve pixel level segmentation of the 586 tumour-liver interface. The algorithm is based on the accurate identification and 587 segmentation of the different tissue types at this interface by using deep neural networks and 588 by taking both cell and tissue characteristics into account. The neural network is employed to 589 identify the tissue type using patches of a certain size. The characterization of cell types within 590 these patches then adds sensitivity, especially at the transition of one tissue type to another. 591 In addition, uncertain regions are classified by analysing the similarity of this region and its 592 neighbour, a concept called 'context-aware tissue region classification'. To train the model at 593 the tissue level, many patches were annotated by pathologists at the Karolinska University 594 Hospital, as belonging to liver parenchyma, fibrosis, necrosis, tumour, or inflammation. At the 595 cell level, the model was trained by pathologists to recognize hepatocytes, cells belonging to 596 fibrotic tissue, tumour cells and inflammatory cells. Once the algorithm succeeded in 597 accurately classifying the tissue types of an entire WSI, rules were developed to detect the 598 growth patterns based on the apposition of different types of tissue at the tumour-liver 599 interface: 'liver-fibrosis-tumour' for the desmoplastic HGP and 'liver-tumour' for the replacement HGP. Extensive analytical and clinical validation is still ongoing. 600

601 The algorithm developed by Jeroen Van der Laak and his team was designed to distinguish 602 CRLM with 100% desmoplastic HGP from liver metastases with any proportion of non-603 desmoplastic HGP by mimicking the visual feature extraction of an entire WSI at once, as done 604 by pathologists<sup>21,22</sup>. Due to the extensive computational power required to process the 605 gigapixel WSIs at once, reduction of dimensionality (or compression) was necessary. This was 606 achieved by training an encoder in a supervised way to solve several representative tasks in 607 computational pathology. This encoder then reduced both the size and the noise level of the WSIs. In a second step, a convolutional neural network was trained using the image-level 608 labels of '100% desmoplastic HGP' and 'any % of non-desmoplastic HGP'. When the algorithm 609 610 was applied to predict the HGP of CRLM, an AUC by ROC analysis of 0.895 was obtained. The 611 algorithm was also able to divide a cohort of 337 patients into two risk categories that 612 predicted OS (HR: 2.35, p<0.001). It appears therefore that the HGP of liver metastases can 613 reliably be assessed through the compression and analysis of the WSIs of H&E-stained sections 614 and that this assessment has prognostic power.

These methods<sup>20,21</sup> demonstrate the power of automated scoring algorithms to assist the pathologist in collecting prognostic information based on parameters reflecting tumour biology. Moreover, when these computer vision algorithms can directly learn from clinical data such as survival, they will also be useful as a biomarker discovery tool<sup>21</sup>.

619

### 620 Angiotropic extravascular migratory metastasis by pericytic mimicry

621 Migration of cancer cells along blood vessels at and distal to the advancing front of primary 622 tumours and metastases has been extensively studied by the team of Lugassy and Barnhill, particularly in melanoma (for review:<sup>33</sup>). During this process of angiotropic extravascular 623 624 migration, cancer cells are in contact with endothelial cells ('angiotropism') via an amorphous 625 matrix that abundantly contains laminin and other constituents of the basement membrane, 626 thereby replacing the pericytes ('pericyte mimicry'). This type of extravascular migration has 627 been proposed as an alternative to the intravascular route of metastatic spread and seems to be driven by cancer cells re-activating embryogenesis-like programs<sup>31,65</sup>. In replacement-type 628 629 but not in desmoplastic liver metastases of melanoma, individual cancer cells can be observed 630 in the liver parenchyma disconnected and at a distance from the tumour-liver interface (Figure 631 6). As such, growth of liver metastases in a replacement pattern and extravascular migration 632 by angiotropism and pericytic mimicry can be regarded as complementary processes 633 representing a continuum of cancer progression with likely common underlying biological 634 mechanisms. To accurately detect extravascular migration of individual cancer cells in liver 635 metastases with a replacement growth pattern, immunohistochemical staining with cancer 636 cell-specific markers is necessary. Studies that quantify the extent of this angiotropic 637 extravascular migration in liver metastases are ongoing. It will be important to determine 638 whether the presence of angiotropic extravascular migration in liver metastases with a 639 replacement HGP contributes to a poorer outcome.

640

### 641 Medical imaging as a tool to identify the HGPs of liver metastases

642 The implementation of the HGPs in clinical practice will depend, in part, on creating the means 643 for recognising the growth patterns without the need for surgical removal of the liver 644 metastases and analysis by a pathologist. Medical imaging may be a promising approach to 645 solve this challenge. Indeed, several smaller studies suggest that CT and MRI images contain 646 information about the growth pattern (see Table 1 of previous guidelines manuscript by van Dam P et al (2017)<sup>1</sup> and of the current guidelines)<sup>66</sup>. This is not surprising, given the major 647 648 histological and biological differences between the desmoplastic and replacement growth 649 pattern. It is, however, only during the last few years that two teams have attempted to 650 identify growth patterns of liver metastases by medical imaging in a more systematic manner. 651 In Erasmus MC, Rotterdam, Starmans and colleagues have extracted more than 500 radiomics 652 features from CT-images of 76 patients with 93 CRC liver metastases with pure desmoplastic

(48%) or pure replacement (52%) HGP<sup>10</sup>. Importantly, these features were extracted from entire metastases, not only from the lesion boundaries. A decision model based on the selection of relevant features and classification of these features by machine learning had a mean area under the curve of 0.69. Adding clinical information to the model did not improve the power to predict the HGPs. Obviously, future studies will have to include metastases with a mixed HGP. Nevertheless, this study is a valuable proof of concept for the utility of this approach.

A team at the Peking University People's Hospital has recently published three studies on the 660 identification of HGPs of CRC liver metastases by medical imaging<sup>8,9,67</sup>. It is important to note 661 that these studies attempt to identify the predominant growth pattern. Cheng and colleagues<sup>8</sup> 662 analysed contrast-enhanced CT-images of 126 CRC liver metastases, of which 68 had a 663 664 predominant (>50%) desmoplastic HGP and 58 had a predominant replacement HGP. Pre-665 contrast and post-contrast CT-images (from both the arterial and portal venous phases) were used. Of each of these 3 phases, 20 radiomics features were selected by an algorithm based 666 667 on minimal redundancy and maximal relevance. A fused decision-tree based signature of the 668 three phases resulted in a predictive model with an area under the curve of 0.94. Adding 669 clinical information or qualitative information provided by the radiologist did not improve the 670 predictive power.

In a similar study, MRI-derived regions, both covering the whole tumour volume as well as the tumour-liver interface specifically, were subjected to radiomic feature extraction in a cohort of 182 CRC liver metastases, of which 59 had a predominant (>50%) desmoplastic HGP and 123 had a predominant replacement HGP<sup>9</sup>. The predictive model that combined clinical characteristics, qualitative imaging data generated by the radiologist and radiomic feature data from the tumour-liver interface had and area under the curve of 0.91.

In their most recent study, the team at the Peking University People's Hospital has used their CT-based radiomics HGP-signature to predict response and PFS in a cohort of 119 patients with liver metastatic CRC treated with a combination of chemotherapy and bevacizumab<sup>67</sup>. Among 346 metastases studied, 206 had a radiological predominant desmoplastic HGP and 140 had a radiological predominant replacement HGP. Patients with only metastases with a predominant desmoplastic HGP only as assessed by radiology had a significantly improved 1year PFS (HR = 0.34; p<0.001).

Although the studies by Cheng J et al (2019)<sup>8</sup>, Han Y et al (2020)<sup>9</sup> and Wei S et al (2021)<sup>67</sup> are 684 685 very promising, validation of the results in larger cohorts by independent research teams and 686 with images acquired in different hospital is still necessary. In addition, at least for patients 687 with CRLM, it will be necessary to select, by means of imaging, those patients who have metastases with a 100% desmoplastic growth pattern. So, even though considerable 688 689 progresses have been made to better determine the HGP prior to resection of the liver 690 metastases, there might still be a need to develop computational tools to integrate as many 691 parameters as feasible to stratify patients more accurately.

- 692
- 693 Biology

# 694 New biological insights into growth patterns through immunohistochemical analyses

695 Why does a liver metastasis in one patient develop a desmoplastic rim, while a metastasis in 696 a different patient has a replacement-type growth pattern, even when the primary tumour 697 type is the same? The full answer to this question and the biological mechanisms that underlie 698 the different growth patterns remain elusive. There are reasons to assume that cancer cell motility and differentiation<sup>41</sup>, angiocrine signals<sup>68</sup> and interactions of cancer cells with 699 hepatocytes<sup>16</sup> and with stromal and inflammatory cells<sup>32</sup> are important factors regulating the 700 701 emergence of a distinct growth pattern. However, the precise mechanisms and the order of 702 events leading to the specific growth patterns remain unclear. There are compelling observations to suggest that systemic treatment can alter the growth pattern<sup>41,61</sup>. Also, given 703 704 that some mouse PDX models can recapitulate the pattern observed in the donor patient, the 705 growth pattern may be, at least in part, determined by cancer cell intrinsic properties<sup>16</sup>. 706 However, this does not exclude epigenetic control and the influence of tumour 707 microenvironment as important further mechanisms<sup>52</sup>.

Based on immunohistochemical stainings performed by the Karolinska team (Carlos
Fernández Moro, Marco Gerling, Béla Bozóky) to map the spatial relationships and phenotypic
states of epithelial and stromal cells, we propose two additional working hypotheses to
explain the biology of the HGPs.

A first working hypothesis is that the replacement growth pattern is the default pattern of growth for cancer cells forming a tumour in the liver. This means that spontaneous or induced transition to the desmoplastic pattern regularly takes place as a second step. An intrinsic and important limitation of determining growth patterns by histological analysis of a resection 716 specimen is that we only get information from a single time point. A non-invasive method to 717 assess the HGPs, such as imaging, would allow longitudinal, repeated determination of HGPs. 718 We may, however, be able to infer information about the history of a liver metastasis by 719 comparing the centre of the tumour with its periphery. Surprisingly, after 720 immunohistochemical analysis, we found remnants of portal triads (branches of the bile duct 721 and of the hepatic artery) in the centre of both replacement and desmoplastic metastases. 722 These portal elements are regularly found to be embedded in specialized portal-type stromal 723 cells expressing Nerve Growth Factor Receptor (NGFR)- and alpha Smooth Muscle Actin 724 (alpha-SMA, Figure 7A). This observation supports a model in which the metastatic tumour 725 co-opts the sinusoidal blood vessels and the portal tract architecture of the liver, a mode of growth that likely is advantageous, both for blood supply and structural support. While portal 726 727 triad co-option is readily identifiable at the tumour-liver interface of replacement-type liver 728 metastases, it may be more subtle in the fibrous rim of the desmoplastic type, where pre-729 existing liver structures appear atrophic and attenuated. Here, immunohistochemistry can be 730 used to identify atrophic remnants of the portal triad. Together, this leads us to propose the 731 hypothesis that replacement growth, in most cases, precedes desmoplastic growth in 732 metastases with the latter HGP. The time point at which the growth patterns may switch and 733 the factors responsible for the proposed conversion remain unclear. There are other 734 observations to support a model in which replacement growth is the default growth pattern 735 of liver metastases. For example, when cancer cells spread within the bile ducts, the cancer 736 cells rest on the basement membrane of the normal biliary epithelial lining and progress by 737 replacing these normal cells and by co-opting the subepithelial stroma (Figure 7B). In addition, 738 we occasionally observe bile ducts as part of the ductular reaction in the desmoplastic rim, in 739 which cancer cells create hybrid cancer cell-cholangiocytes ductular structures (Figure 7C). 740 Although these histological observations need further validation and quantification, they do support other observations consistent with growth pattern plasticity. Indeed, resistance to 741 742 chemotherapy can coincide with a switch to the replacement HGP<sup>41,59</sup>, while pre-operative 743 chemotherapy converts metastases in some patients from replacement to desmoplastic 744 HGP<sup>61</sup>. Also, during disease progression in patients with recurrent colorectal liver metastases, 745 there is an evolution towards the more aggressive replacement HGP, as observed by analysing 746 repeated resections<sup>18</sup>.

747 A second working hypothesis is that the fibrous rim surrounding desmoplastic liver metastases 748 and the portal tract are biologically related. This hypothesis is supported by two observations. 749 Firstly, the stromal cells of the desmoplastic rim, and especially of the outer portion of the rim 750 neighbouring the surrounding liver parenchyma, strongly co-express NGFR and alpha-SMA, 751 indicative of a "myofibroblast" or "activated fibroblast" phenotype (Figure 7D). NGFR is expressed by progenitors of Ito/stellate cells and of portal fibroblasts in the foetal liver<sup>69,70</sup> 752 753 and this receptor also plays a crucial role during pathological liver fibrosis by inducing 754 fibrogenic gene expression, for example of the Transforming Growth Factor beta1-gene, in activated (myo)fibroblasts<sup>71-73</sup>. Secondly, by co-immunostaining for CK18, as a marker of 755 756 hepatocytes, and CK19, as a marker of cholangiocytes, we often observe mosaic ductular structures in the desmoplastic rim composed of a mixture of cells with a hepatocyte-like and 757 a cholangiocyte-like phenotype (Figure 7E). Activated fibroblasts are known to induce 758 759 cholangiocyte differentiation in hepatic stem-like cells (for example, via Jagged-1 and 760 Hedgehog ligands) and this process partly relies on NGFR expression in the activated liver 761 fibroblasts<sup>73,74</sup>. NGFR-expressing and activated, alpha-SMA-positive fibroblasts in the 762 desmoplastic rim may therefore activate extracellular matrix production and induce a ductular 763 reaction by engaging bipotent progenitors, resembling portal tract development as well as liver fibrosis in other pathological conditions involving liver injury<sup>75</sup>. In the metastasis context, 764 destruction of liver cells by the invading tumour, inflammation, and damage of the 765 peritumoral liver tissue are potential mechanisms of liver injury. 766

767

### 768 Hypotheses to explain the biology of the distinct histopathological growth patterns

769 There is currently no satisfactory explanation for the specific biology of each of the 770 histopathological growth patterns. Table 6 therefore summarizes some hypotheses to explain 771 the distinct phenotypes of the desmoplastic and replacement growth patterns. These 772 hypotheses are derived from histopathological insights, pre-clinical animal models and the 773 comparison with organ development in the embryo. The hypotheses listed in Table 6 are not 774 mutually exclusive and elements of each probably contribute to the specific growth patterns 775 of liver metastases. In addition, some hypotheses outlined only address individual growth 776 patterns.

Taken together, cancer cells within a liver metastasis exhibiting a replacement growth patternappear to adapt to the microenvironment of the liver parenchyma and may therefore be

sensitive to a liver pro-metastatic reaction of the patient<sup>76</sup>, while cancer cells of a desmoplastic 779 780 metastasis create their own microenvironment. Against this background, it could be argued 781 that cancer cells in a replacement metastasis behave like hepatocytes or hepatocyte 782 progenitor cells communicating with the liver niche (for example with the co-opted sinusoidal 783 endothelial cells), whereas cancer cells in a desmoplastic metastasis more autonomously form 784 a tumour that resembles the primary tumour. The plasticity of the growth patterns suggested 785 by clinical observations appears to indicate that this divergent behaviour of cancer cells in the 786 liver is not, or at least not entirely, the result of a different mutational gene profile, but rather of epigenetic events and the ability to respond to stimuli from the microenvironment, such as 787 soluble factors elicited by the liver pro-metastatic reaction<sup>76</sup> and liver immune responses<sup>77</sup>. 788

- 789
- 790

#### 791 Discussion

792 Since the publication of the first consensus guidelines<sup>1</sup>, numerous studies have been conducted describing the impact of HGPs on the outcome of patients with liver metastases 793 794 (Table 1). These studies are not limited to liver metastases from colorectal carcinoma, but also 795 include patients with liver metastases from breast carcinoma, melanoma, and pancreatic adenocarcinoma<sup>5,42,44,45</sup>. The association between replacement HGP and poorer patient 796 797 outcome, independent of the primary tumour type, has been confirmed by these new studies. 798 A new cut-off to categorize patients with CRLM according to the HGPs is presented in the 799 current guidelines. This cut-off is derived from the observation in a large multi-centre cohort 800 of patients that any proportion of non-desmoplastic HGP, however small, is associated with a 801 worse prognosis. The extent of non-desmoplastic features within the metastases in itself does 802 not seem to modulate outcome any further. We have therefore updated the guidelines for 803 scoring the HGPs of CRLM for the purposes of prognostication of patients, and we propose 804 herein some immunohistochemical assays that may help to identify the growth patterns in 805 more challenging situations, such as in the presence of dense inflammation or systemic 806 treatment effects.

The tumour-type independent prognostic value of the HGPs fuels the idea that the biology of the replacement HGP is fundamentally different from that of the desmoplastic growth pattern. Some of these differences have been well described. In the desmoplastic growth pattern, a dense immune-inflammatory cell infiltrate surrounds the fibrous rim, while the replacement growth pattern has the characteristics of an immune desert, especially when no chemotherapy is involved<sup>2-4,32,78</sup>. The desmoplastic pattern has angiogenic vascular hot spots in between cancer cell nests and hypoxic areas while the replacement growth pattern shows a uniformly high vessel density and minimal hypoxia, probably because of efficient vessel cooption<sup>30,38,41</sup>. Consequently, replacement-type liver metastases are also metabolically more active than desmoplastic liver metastases, as demonstrated by FDG-PET analyses<sup>79</sup>.

817 A striking morphological difference between the growth patterns lies in the organisation of 818 the cancer cells and the interaction with the host liver tissue. In replacement-type liver 819 metastases, cancer cells mimic hepatocytes by an arrangement in solid cell plates in between 820 the co-opted sinusoidal blood vessels. This type of growth clearly resembles the 'vascularizing' organogenesis' that takes place when the liver develops in the embryo and may also be guided 821 by instructive signals originating in the liver sinusoidal endothelial cells<sup>80-83</sup>. Accordingly, 822 823 cancer cells belonging to replacement-type liver metastases seem to hijack the embryological 824 program of liver development with the resulting tumour adopting the histological architecture 825 of liver tissue. The work of Teng and team<sup>52</sup> supports this hypothesis. They have shown that 826 CRLM, when compared with primary colorectal cancer, simultaneously gain liver-specific and 827 lose colon-specific transcription programs. They also showed that this is the result of a 828 reprogrammed enhancer landscape. Enhancers are regulatory elements in the genome that 829 are influenced by the environment and, as such, play an important role in tissue-specific gene 830 expression patterns and cell identity. However, whether differences in the enhancer 831 landscape can also explain the morphological differences between the replacement and the 832 desmoplastic growth pattern of liver metastases still needs to be investigated. During 833 desmoplastic growth of liver metastases, the cancer cells arrange in more differentiated 834 structures, not as cancer cell plates, and resemble the glandular structures of primary 835 colorectal and breast cancer. In other words, desmoplastic liver metastases morphologically mimic the primary tumour they originate from, where cancer cells typically induce a 836 837 continuous wound-healing response with inflammation, fibrosis, coagulation, and 838 angiogenesis. This probably involves tumour-host interactions that are active in the primary 839 tumour and epithelial-stromal interactions of the normal tissue counterpart (e.g., colon, 840 breast, etc.). These hypothetical and morphology-driven views on the divergent biological 841 mechanisms of the liver metastasis growth patterns are now being investigated by bulk RNA-842 sequencing, single cell RNA-sequencing, in situ RNA-sequencing and multiplex immunohistochemistry. PDX-models and co-organoids derived from patient liver metastases
are used for functional validation. Alternative hypotheses to explain the distinct
histopathological growth patterns have been listed in Table 6.

846 At a single time-point, patients often have liver metastases consisting of both desmoplastic 847 and replacement HGP regions. This is, for example, true for about 60% of all patients with resected CRLM<sup>18</sup>, independent of whether chemotherapy was administered before surgery. 848 849 Co-occurrence of distinct HGPs thus seems to be part of the growth process of liver metastases 850 and this may be the consequence of transitioning from one HGP to another. We now propose the working hypothesis, based on immunohistochemical analyses, that the replacement HGP 851 852 is the default growth pattern of liver metastases. Although there are data to support the view 853 that pre-surgery chemotherapy can induce desmoplastic growth in some metastases<sup>18,61</sup> and 854 that a switch to replacement growth can occur upon resistance to systemic treatment<sup>41</sup>, the 855 cellular and molecular mechanisms responsible for these transitions from one growth pattern 856 to another remain to be elucidated. What these and other findings do seem to suggest is that 857 epigenetic processes drive the growth patterns rather than mutational hardwiring. Recently, 858 the concept of 'histostasis', driven by cancer cell-autonomous properties, has been put 859 forward to explain the morphological resemblance between metastatic tissue and the corresponding primary tumour<sup>84</sup>. As a complement, we propose here to introduce the concept 860 of 'histokinesis', a process driven by cancer cell-responsiveness to instructive host tissue-861 derived signals, such as the pro-metastatic liver reaction<sup>76</sup>, to explain the clear morphological 862 863 differences between the primary tumour and, for example, replacement-type liver 864 metastases. This is probably a more general biological concept, given the observations of similar growth patterns in, for example, lung metastases<sup>56,85-87</sup>. 865

866 The plasticity of the growth patterns might be exploited in future therapeutic strategies. A 867 prerequisite to feasibility would be a continuous evaluation of the growth pattern in a pre-868 surgical setting of systemic treatment. This implies a reliable non-invasive method for 869 repeatedly identifying the growth patterns during the patient treatment. Table 1 highlights 870 the initiatives of several teams worldwide to develop algorithms to assess the growth patterns 871 of liver metastases by medical imaging<sup>8-10,66</sup>. In addition, several studies are still ongoing with results to be expected in the coming years. As an alternative, circulating markers in the blood 872 873 of patients may be useful to identify the prevailing growth pattern at a certain moment in

time. A study by Tabariès<sup>16</sup> proposes exosome-derived claudin-profiling as a tool to predict
the growth pattern of CRLM.

876 The role of systemic treatment, either neo-adjuvant or adjuvant, for patients with a priori 877 resectable metachronous CRLM remains unclear. In many countries, patients will receive 878 standard post-operative chemotherapy, following metastasectomy performed with curative 879 intent. Although the benefit of adjuvant treatment is still to be fully appreciated, surgery alone 880 is often not considered. To face the problem of potentially low accrual in a study that 881 compares surgery alone with surgery combined with adjuvant chemotherapy, we suggest 882 limiting the study population to those patients with liver metastases that exclusively have the 883 desmoplastic growth pattern upon careful pathological evaluation of the resected metastases, as a first approach. Alternatively, and only when a non-invasive pre-operative marker of the 884 885 HGPs becomes available (as liver biopsies to evaluate the HGP are not suitable), a window of 886 opportunity study could be envisioned to examine the role of specific treatments for 887 replacement and desmoplastic liver metastases in patients with (borderline) resectable liver 888 metastases. For example, given the distinct immune contexture of each of the growth 889 patterns, the choice of immunotherapy may need to be adapted to the growth pattern of the 890 liver metastases. It is also unclear whether the clinically relevant systemic immunosuppressive 891 effects of the presence of liver metastases, leading to reduced benefit from immune checkpoint inhibitors, may be growth pattern-dependent<sup>88</sup>. A better insight into the 892 893 interaction of liver-metastatic cancer cells with the complex immune environment of the liver will contribute to understanding the biology of the HGPs<sup>77</sup>. 894

In conclusion, we provide updated guidelines for scoring the histopathological growth patterns of liver metastases. These are of importance not only to implement the HGPs in the clinical care of patients with liver metastatic cancer, but also to properly conduct studies that seek to identify the biological basis for these growth patterns. The latter is important to better understand the heterogeneity of liver metastases, and thus perhaps also of tumour expansion in other organs where similar growth patterns have been described, such as in the lungs<sup>56,87</sup>.

- 901
- 902
- 903
- 904

#### 905 Figure and table legends

906 Figure 1. The histopathological growth patterns of liver metastases (H&E images). (A) Low 907 magnification image of a CRC liver metastasis with a desmoplastic HGP. (B) & (C) Higher 908 magnification of the tumour-liver interface of CRC liver metastases with a desmoplastic HGP. 909 The blue double headed arrow indicates the desmoplastic rim that separates the carcinoma 910 from the liver parenchyma. The green arrowheads indicate the immune cell infiltrate which is 911 typically located at the transition between the desmoplastic rim and the liver parenchyma. 912 The tumours show glandular differentiation and cell detritus in the lumina of these glandular 913 structures, reminiscent of the histology of a primary CRC (white arrowheads). (D) Low 914 magnification image of a CRC liver metastasis with a replacement HGP. The green arrowheads 915 indicate the tumour-liver interface. There is no glandular differentiation: cancer cells from 916 solid nests and trabeculae. (E) & (F) Higher magnification of the tumour-liver interface of CRC 917 liver metastases with a replacement HGP. The green arrowheads indicate contact between 918 cancer cells and hepatocytes. In (E), cancer cells form cell plates that are in continuity with the 919 liver cell plates. A co-opted sinusoidal blood vessel is marked by the blue arrowheads. In (F), 920 the liver cell plates are pushed aside but cancer cells are still in contact with hepatocytes while 921 invading into these liver cell plates (green arrowheads). (G) Low magnification image of a CRC 922 liver metastasis with a pushing HGP. (H) On higher magnification, a sharp tumour-liver 923 interface is noticed without desmoplastic rim and without cancer cells invading into the liver 924 parenchyma. Often metastases with a pushing HGP produce mucin, as shown in this example. 925 (I) Lobular breast carcinoma liver metastasis with a sinusoidal HGP (autopsy case). Cancer cells 926 are located within the lumen of sinusoidal blood vessels (green asterisks), in between liver cell 927 plates (blue asterisks). Red blood cells are intermingled with the cancer cells (blue 928 arrowheads). (J) Low magnification image of intrabiliary tumour growth (CRC) in a portal tract. 929 The structures constituting a portal tract are present: artery branches (A), vein branch (V), nerve bundle (N), and branches of the bile duct (B), in this case filled with cancer cells. (K) 930 931 Higher magnification of the left bile duct branch of image J. The normal bile duct epithelium 932 (blue arrowheads) is still present but is replaced by cancer tissue that fills the lumen of the 933 bile duct branch.

934

Figure 2. Kaplan–Meier curves depicting overall and disease-free survival of patients withcolorectal liver metastases, stratified by the new cut-off for histopathological growth patterns

937 categorisation (A to D) and by the predominant growth pattern (E and F). N = 1931 patients938 with resected colorectal liver metastases.

939

Figure 3. H&E image of the escape phenotype. (A) Low magnification image with large necrotic
areas in the centre of the CRC liver metastasis, remnants of the desmoplastic rim (d) and vital
replacement-type outgrowth at the tumour-liver interface (arrows). (B) Higher magnification
of the 'escape' area with replacement HGP. Li, liver; Me, metastatic tumour tissue.

944

945 Figure 4. Immunohistochemical staining as an aid to HGP scoring

A. Detection of the replacement HGP in the presence of an extensive immune cell infiltrate that obscures the tumour-liver interface by identification of cancer cell-hepatocyte contact (green arrowheads) at the tumour-liver interface and co-option of hepatocytes (blue arrowheads) in liver lobules undergoing replacement by cancer cells. CK19 (DAB, brown) stains colorectal cancer cells. CK18 (AP, red) stains hepatocytes. Left: low magnification; Right: high magnification.

B. Detection of the pushing-type replacement (type 2) HGP in which the hepatocyte plates are
slender (yellow dotted area) and arranged in parallel with the tumour-liver interface. Green
arrowheads indicate cancer cell-hepatocyte contact and blue arrowheads hepatocyte cooption. CK19 (DAB, brown) stains colorectal cancer cells. CK18 (AP, red) stains hepatocytes.

956 C. Prominent ductular reaction at the tumour-liver interface in the desmoplastic HGP. Areas 957 of ductular reaction (green arrowheads) are present in the outer region of the fibrous rim 958 (green dotted region). Cancer cells are (blue arrow) identified in the metastasis centre, 959 adjacent to necrotic areas (orange star). Right. Detail of the ductular reaction at the tumour-960 liver interface. Cholangiocytes (CK7+) form irregular, angulated, anastomosing ductuli. Note 961 the presence of interspersed cancer cells (CK20+, blue arrows) within the ductuli, forming 962 common ductular structures. CK20 (DAB, brown) stains colorectal cancer cells. CK7 (AP, red) 963 stains cholangiocytes.

D. Detection of intrabiliary tumour growth. A discontinuous lining of biliary epithelial cells (blue arrows) can be identified surrounding colorectal cancer cells (sparsely positive for CK20 in this case) with focal contact between colorectal cancer cells and biliary epithelial cells (green stars). CK20 (DAB, brown) stains colorectal cancer cells. CK7 (AP, red) stains cholangiocytes. Left: low magnification; right: high magnification.

969

970 Figure 5.

971 Patient-derived xenograft (PDX) mice models for CRC liver metastases with a desmoplastic972 and a replacement HGP (H&E images).

973 A. Resected liver metastasis with a desmoplastic HGP (Left) and corresponding xenograft PDX-

974 model (Right). Green arrows indicate the desmoplastic rim in the patient sample and in the
975 liver metastasis of the mouse (PDX#35, see supplementary table 2 in Tabariès S, 2021)<sup>16</sup>.

B. Resected liver metastasis with a replacement HGP (Left) and corresponding xenograft PDXmodel (Right). Green arrows indicate some of the areas in which the cancer cells grow into
the liver cell plates and contact the hepatocytes, both in the patient sample and in the liver

979 metastasis of the mouse (PDX#30, see supplementary table 2 in Tabariès S, 2021)<sup>16</sup>.

980

Figure 6. Images of melan-A immunostaining of melanoma liver metastases. (A) High magnification images of the tumour-liver interface of a melanoma liver metastasis with a replacement HGP. Small groups of melanoma cells and individual melanoma cells have migrated away from the tumour-liver interface (arrows). (B) High magnification images of the tumour-liver interface of a melanoma liver metastasis with a desmoplastic HGP. No migration of melanoma cells in the desmoplastic rim, marked by 'D'.

987

Figure 7. New biological insights into growth patterns through immunohistochemical analyses 988 A. Remnants of portal zones in the centre of colorectal liver metastases. Left. Detail of a 989 990 tumour centre in a metastasis with a predominant replacement HGP showing remnant of a 991 portal zone with bile duct (green arrowhead) and hepatic artery branch (blue arrowhead). 992 Note colonization by viable cancer cells of the periportal limiting plate region (orange 993 arrowhead). Caldesmon (DAB, brown) stains smooth muscle cells, mainly in the media layer 994 of the hepatic artery. CK7 (DAB, brown) stains bile duct epithelium. CD34 (AP, red) stains the 995 endothelium of the hepatic artery and of the stromal capillary network. Right. Tumour centre 996 in a metastasis with a desmoplastic HGP showing multiple remnants of portal zones between 997 lobules that have undergone complete replacement by cancer cells (orange arrowheads). The 998 bile ducts (green arrows) and branches of the hepatic artery (blue arrows) are embedded in 999 NGFR+ portal stroma (yellow arrowheads). CD146 (DAB, brown) stains smooth muscle cells 1000 (mainly in the wall of hepatic arteries) and areas of ductular reaction. NGFR (AP, red) stains1001 activated portal fibroblasts and stellate cells.

B. Intrabiliary tumour growth in a CRC liver metastasis. Left. Densely packed cancer cells (green stars) show exophytic growth and fill the bile duct lumen. Portions of preserved biliary epithelium (blue arrows) are still identified. Right. Detail illustrating the replacement-like growth of cancer cells, which progress by establishing direct contact with and replacing the cholangiocytes while co-opting their basal membrane. CK20 (DAB, brown) stains colorectal cancer cells. CK7 (AP, red) stains cholangiocytes.

1008 C. Hybrid cancer cell-cholangiocyte ductular structures. Ductular reaction in the desmoplastic 1009 rim with cancer cells (CK20-positive, DAB, brown) forming hybrid structures with 1010 cholangiocytes (CK7-positive, AP, red).

1011 D. Stromal cell heterogeneity in a metastasis with a desmoplastic HGP. Top. The outer region of the desmoplastic rim stains strongly positively for NGFR (Left, green arrows) and  $\alpha$ -smooth 1012 1013 muscle actin (alpha-SMA) (Right, green arrowheads), consistent with activated portal/stellate 1014 cell stroma. In contrast, the stroma in the metastasis centre is positive for alpha-SMA but 1015 negative for NGFR, indicating a desmoplastic character (Left and right, blue arrows). Bottom. 1016 Reference illustrations of activated portal stroma in non-neoplastic liver, showing (Left) NGFR 1017 and (Right) alpha-SMA immunoreactivity (Left and right, green arrows). CD146 (DAB, brown) stains vascular and sinusoidal endothelium and smooth muscle in branches of the hepatic 1018 1019 artery and portal vein. NGFR (AP, red) stains activated portal fibroblasts and stellate cells. 1020 CK18 (DAB, brown) stains hepatocytes and cholangiocytes. Alpha-SMA (AP, red) stains 1021 activated portal fibroblasts, stellate cells and desmoplasia-associated myofibroblasts.

1022 E. Ductular reaction in the desmoplastic rim with cells with a hepatocyte-like (CK18-positive,

1023 AP, red) and a cholangiocytes-like (CK18, DAB, brown) phenotype (green arrows).

1024

1025

1026 Table 1. Overview of studies on the histopathological growth patterns of liver metastases, in

addition to the studies listed in table 1. of the first guidelines paper (Van Dam et al 2017).

1028 Abbreviations: CGH = comparative genomic hybridization; CRC = colorectal cancer; CRISPR =

1029 clustered regularly interspaced short palindromic repeats; CT = computed tomography; DFS =

1030 disease-free survival; dHGP = desmoplastic histopathological growth pattern; EMT = 1031 epithelial-to-mesenchymal transition; H&E = haematoxylin-and-eosin stained; HGP =

histopathological growth pattern; HR = hazard's ratio; MMP = matrix metalloprotease; MRI =
magnetic resonance imaging; mCRS = metabolic clinical risk score; NOD scid = nonobese
diabetic severe combined immunodeficiency; MMPI = macro-metastasis/organ parenchyma
interface; OS = overall survival; PFS = progression-free survival; PDX = patient-derived
xenograft; RFS = relapse free survival; rHGP = replacement histopathological growth pattern;
ROI = region of interest; TLI = tumour-liver interface; VEGF = vascular endothelial growth
factor; WES = whole exome sequencing.

1039

1040 Table 2. Key histopathological characteristics of the growth patterns of liver metastases.

1041

Table 3. Clinicopathological baseline and treatment characteristics of the cohort of 1931
patients used to evaluate the impact on outcome of the new cut-off for patient categorisation
according to the histopathological growth pattern of resected colorectal liver metastases.

Abbreviations: ASA = American Society of Anaesthesiologists; CEA = carcinoembryonic
antigen; CRLM = colorectal liver metastasis; Erasmus MC = Erasmus Medical Center Cancer
Institute; IQR = interquartile range; MSKCC = Memorial Sloan Kettering Cancer Center;
Radboud UMC = Radboud University Medical Center.

1049

Table 4. Overall and disease-free survival estimates for different histopathological growth pattern cut-offs in 1931 patients treated with curative intent resection for colorectal liver metastases.

Abbreviations: ASA = American Society of Anaesthesiologists; CEA = carcinoembryonic antigen; CRLM = colorectal liver metastasis; HGP = histopathological growth pattern; NA = not available.

1056

1057 Table 5. Updated standard method for histopathological growth pattern assessment of liver1058 metastases.

1059

1060 Table 6. Hypotheses to explain the biology of the different histopathological growth patterns1061 of liver metastases, including supporting evidence and/or supporting arguments.

1062

1063
medRxiv preprint doi: https://doi.org/10.1101/2022.04.07.22273504; this version posted April 10, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

## 1065 References

- van Dam, P.J., van der Stok, E.P., Teuwen, L.A., Van den Eynden, G.G., Illemann, M.,
   Frentzas, S. et al. International consensus guidelines for scoring the histopathological
   growth patterns of liver metastasis. *Br J Cancer* **117**, 1427-1441 (2017).
- Stremitzer, S., Vermeulen, P., Graver, S., Kockx, M., Dirix, L., Yang, D. et al. Immune
   phenotype and histopathological growth pattern in patients with colorectal liver
   metastases. *Br J Cancer* **122**, 1518-1524 (2020).
- Liang, J.Y., Xi, S.Y., Shao, Q., Yuan, Y.F., Li, B.K., Zheng, Y. et al. Histopathological growth
   patterns correlate with the immunoscore in colorectal cancer liver metastasis patients
   after hepatectomy. *Cancer Immunol Immunother* 69, 2623-2634 (2020).
- Hoppener, D.J., Nierop, P.M.H., Hof, J., Sideras, K., Zhou, G., Visser, L. et al. Enrichment
   of the tumour immune microenvironment in patients with desmoplastic colorectal
   liver metastasis. *Br J Cancer* **123**, 196-206 (2020).
- Watanabe, K., Mitsunaga, S., Kojima, M., Suzuki, H., Irisawa, A., Takahashi, H. et al. The
  "histological replacement growth pattern" represents aggressive invasive behavior in
  liver metastasis from pancreatic cancer. *Cancer Med* **9**, 3130-3141 (2020).
- Messaoudi, N., Henault, D., Stephen, D., Cousineau, I., Simoneau, E., Rong, Z. et al.
   Prognostic implications of adaptive immune features in MMR-proficient colorectal
   liver metastases classified by histopathological growth patterns. *Br J Cancer* (2022).
- 1084 7. Gulia, S., Khurana, S., Shet, T. & Gupta, S. Radiographically occult intrasinusoidal liver
  1085 metastases leading to hepatic failure in a case of breast cancer. *BMJ Case Rep* 2016,
  1086 (2016).
- Cheng, J., Wei, J., Tong, T., Sheng, W., Zhang, Y., Han, Y. et al. Prediction of
   Histopathologic Growth Patterns of Colorectal Liver Metastases with a Noninvasive
   Imaging Method. Ann Surg Oncol 26, 4587-4598 (2019).
- Han, Y., Chai, F., Wei, J., Yue, Y., Cheng, J., Gu, D. et al. Identification of Predominant
  Histopathological Growth Patterns of Colorectal Liver Metastasis by Multi-Habitat and
  Multi-Sequence Based Radiomics Analysis. *Front Oncol* **10**, 1363 (2020).
- Starmans, M.P.A., Buisman, F.E., Renckens, M., Willemssen, F., van der Voort, S.R.,
   Groot Koerkamp, B. et al. Distinguishing pure histopathological growth patterns of
   colorectal liver metastases on CT using deep learning and radiomics: a pilot study. *Clin Exp Metastasis* 38, 483-494 (2021).
- 109711.Alzubi, M.A., Sohal, S.S., Sriram, M., Turner, T.H., Zot, P., Idowu, M. et al. Quantitative1098assessment of breast cancer liver metastasis expansion with patient-derived1099xenografts. Clin Exp Metastasis 36, 257-269 (2019).
- 1100 12. Piquet, L., Dewit, L., Schoonjans, N., Millet, M., Berube, J., Gerges, P.R.A. et al. Synergic
  1101 Interactions Between Hepatic Stellate Cells and Uveal Melanoma in Metastatic
  1102 Growth. *Cancers (Basel)* **11**, (2019).
- Vlachogiannis, G., Hedayat, S., Vatsiou, A., Jamin, Y., Fernandez-Mateos, J., Khan, K. et
   al. Patient-derived organoids model treatment response of metastatic gastrointestinal
   cancers. Science 359, 920-926 (2018).
- 1106 14. Ibrahim, N.S., Lazaris, A., Rada, M., Petrillo, S.K., Huck, L., Hussain, S. et al.
  1107 Angiopoietin1 Deficiency in Hepatocytes Affects the Growth of Colorectal Cancer Liver
  1108 Metastases (CRCLM). *Cancers (Basel)* 12, (2019).
- 1109
  15. Masaki, S., Hashimoto, Y., Kunisho, S., Kimoto, A. & Kitadai, Y. Fatty change of the liver
  1110 microenvironment influences the metastatic potential of colorectal cancer. *Int J Exp*1111 *Pathol* 101, 162-170 (2020).

- 1112 16. Tabaries, S., Annis, M.G., Lazaris, A., Petrillo, S.K., Huxham, J., Abdellatif, A. et al. 1113 Claudin-2 promotes colorectal cancer liver metastasis and is a biomarker of the 1114 replacement type growth pattern. *Commun Biol* **4**, 657 (2021).
- 1115 17. Bartlett, A.Q., Pennock, N.D., Klug, A. & Schedin, P. Immune Milieu Established by
  1116 Postpartum Liver Involution Promotes Breast Cancer Liver Metastasis. *Cancers (Basel)*1117 13, (2021).
- 1118 18. Galjart, B., Nierop, P.M.H., van der Stok, E.P., van den Braak, R., Hoppener, D.J.,
  1119 Daelemans, S. et al. Angiogenic desmoplastic histopathological growth pattern as a
  1120 prognostic marker of good outcome in patients with colorectal liver metastases.
  1121 Angiogenesis 22, 355-368 (2019).
- 19. Hoppener, D.J., Galjart, B., Nierop, P.M.H., Buisman, F.E., van der Stok, E.P., Coebergh
  van den Braak, R.R.J. et al. Histopathological Growth Patterns and Survival After
  Resection of Colorectal Liver Metastasis: An External Validation Study. *JNCI Cancer Spectr* 5, pkab026 (2021).
- 20. Zhaoyang, X., Carlos Fernádez, M., Danyil, K., Béla, B., Le, D. & Qianni, Z., *Tissue Region*1127 *Growing for Hispathology Image Segmentation*, in *Proceedings of the 2018 3rd*1128 *International Conference on Biomedical Imaging, Signal Processing*. 2018, Association
  1129 for Computing Machinery: Bari, Italy.
- 1130 21. Tellez, D., Höppener, D., Verhoef, C., Grünhagen, D., Nierop, P., Drozdzal, M. et al.
  1131 *Extending unsupervised neural image compression with supervised multitask learning*.
  1132 in *Medical Imaging with Deep Learning*. 2020. PMLR.
- 113322.Tellez, D., Litjens, G., van der Laak, J. & Ciompi, F. Neural Image Compression for1134Gigapixel Histopathology Image Analysis. IEEE Trans Pattern Anal Mach Intell 43, 567-1135578 (2021).
- Nierop, P.M.H., Galjart, B., Hoppener, D.J., van der Stok, E.P., Coebergh van den Braak,
  R.R.J., Vermeulen, P.B. et al. Salvage treatment for recurrences after first resection of
  colorectal liver metastases: the impact of histopathological growth patterns. *Clin Exp Metastasis* 36, 109-118 (2019).
- 1140 24. Nierop, P.M.H., Hoppener, D.J., van der Stok, E.P., Galjart, B., Buisman, F.E.,
  1141 Balachandran, V.P. et al. Histopathological growth patterns and positive margins after
  1142 resection of colorectal liver metastases. *HPB (Oxford)* 22, 911-919 (2020).
- Buisman, F.E., Van der Stok, E.P., Galjart, B., Vermeulen, P.B., Balachandran, V.P.,
  Coebergh van den Braak, R.R.J. et al. Histopathological growth patterns as biomarker
  for adjuvant systemic chemotherapy in patients with resected colorectal liver
  metastases. *Clin Exp Metastasis* (2020).
- 114726.Masson, P. Les tumeurs. Traité De Pathologie Et Thérapie Appliquées27, 572-5741148(1923).
- 1149 27. Hamperl, H. Die morphologie der tumoren. Lehrbuch Der Allgemeinen Pathologie Und
  1150 Der Pathologischen Anatomie 6, 243-244 (1956).
- 115128.Elias, H. & Bouldin, R.F. Reaction of the normal liver parenchyma to metastatic1152carcinoma. Acta Hepatosplenol **9**, 357-386 (1962).
- 115329.Elias, H., Bierring, F. & Grunnet, I. Cellular Changes in the Vicinity of Metastatic1154Carcinoma, Observed by Light and Electron Microscopy. Oncologia 18, 210-24 (1964).
- 30. Vermeulen, P.B., Colpaert, C., Salgado, R., Royers, R., Hellemans, H., Van Den Heuvel,
  E. et al. Liver metastases from colorectal adenocarcinomas grow in three patterns with
  different angiogenesis and desmoplasia. *J Pathol* **195**, 336-42 (2001).

medRxiv preprint doi: https://doi.org/10.1101/2022.04.07.22273504; this version posted April 10, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

- 1158 31. Latacz, E., Caspani, E., Barnhill, R., Lugassy, C., Verhoef, C., Grunhagen, D. et al.
  1159 Pathological features of vessel co-option versus sprouting angiogenesis. *Angiogenesis*1160 23, 43-54 (2020).
- 1161 32. van Dam, P.J., Daelemans, S., Ross, E., Waumans, Y., Van Laere, S., Latacz, E. et al.
  1162 Histopathological growth patterns as a candidate biomarker for immunomodulatory
  1163 therapy. *Semin Cancer Biol* **52**, 86-93 (2018).
- 1164 33. Lugassy, C., Kleinman, H.K., Vermeulen, P.B. & Barnhill, R.L. Angiotropism, pericytic
  1165 mimicry and extravascular migratory metastasis: an embryogenesis-derived program
  1166 of tumor spread. *Angiogenesis* 23, 27-41 (2020).
- 116734.Allison, K.H., Fligner, C.L. & Parks, W.T. Radiographically occult, diffuse intrasinusoidal1168hepatic metastases from primary breast carcinomas: a clinicopathologic study of 31169autopsy cases. Arch Pathol Lab Med 128, 1418-23 (2004).
- Simone, C., Murphy, M., Shifrin, R., Zuluaga Toro, T. & Reisman, D. Rapid liver
  enlargement and hepatic failure secondary to radiographic occult tumor invasion: two
  case reports and review of the literature. *J Med Case Rep* 6, 402 (2012).
- 117336.Watson, A.J. Diffuse intra-sinusoidal metastatic carcinoma of the liver. J Pathol1174Bacteriol **69**, 207-17 (1955).
- 117537.Vaideeswar, P., Munot, S., Rojekar, A. & Deodhar, K. Hepatic diffuse intra-sinusoidal1176metastases of pulmonary small-cell carcinoma. J Postgrad Med 58, 230-1 (2012).
- Stessels, F., Van den Eynden, G., Van der Auwera, I., Salgado, R., Van den Heuvel, E.,
  Harris, A.L. et al. Breast adenocarcinoma liver metastases, in contrast to colorectal
  cancer liver metastases, display a non-angiogenic growth pattern that preserves the
  stroma and lacks hypoxia. *Br J Cancer* **90**, 1429-36 (2004).
- Hoppener, D.J., Nierop, P.M.H., Herpel, E., Rahbari, N.N., Doukas, M., Vermeulen, P.B.
  et al. Histopathological growth patterns of colorectal liver metastasis exhibit little
  heterogeneity and can be determined with a high diagnostic accuracy. *Clin Exp Metastasis* 36, 311-319 (2019).
- 118540.Terayama, N., Terada, T. & Nakanuma, Y. Histologic growth patterns of metastatic1186carcinomas of the liver. Jpn J Clin Oncol **26**, 24-9 (1996).
- 1187 41. Frentzas, S., Simoneau, E., Bridgeman, V.L., Vermeulen, P.B., Foo, S., Kostaras, E. et al.
  1188 Vessel co-option mediates resistance to anti-angiogenic therapy in liver metastases.
  1189 Nat Med 22, 1294-1302 (2016).
- Bohlok, A., Vermeulen, P., Leduc, S., Latacz, E., Botzenhart, L., Richard, F. et al.
  Association between the histopathological growth patterns of liver metastases and
  survival after hepatic surgery in breast cancer patients. *NPJ Breast Cancer* 6, 64 (2020).
- 119343.Horn, S.R., Stoltzfus, K.C., Lehrer, E.J., Dawson, L.A., Tchelebi, L., Gusani, N.J. et al.1194Epidemiology of liver metastases. Cancer Epidemiol 67, 101760 (2020).
- Harnhill, R., Vermeulen, P., Daelemans, S., van Dam, P.J., Roman-Roman, S., Servois, V.
  et al. Replacement and desmoplastic histopathological growth patterns: A pilot study
  of prediction of outcome in patients with uveal melanoma liver metastases. *J Pathol Clin Res* 4, 227-240 (2018).
- Barnhill, R., van Dam, P.J., Vermeulen, P., Champenois, G., Nicolas, A., Rawson, R.V. et
  al. Replacement and desmoplastic histopathological growth patterns in cutaneous
  melanoma liver metastases: frequency, characteristics, and robust prognostic value. J *Pathol Clin Res* 6, 195-206 (2020).

- 46. Grossniklaus, H.E., Zhang, Q., You, S., McCarthy, C., Heegaard, S. & Coupland, S.E.
  Metastatic ocular melanoma to the liver exhibits infiltrative and nodular growth
  patterns. *Hum Pathol* 57, 165-175 (2016).
- 47. Grossniklaus, H.E. Progression of ocular melanoma metastasis to the liver: the 2012
  1207 Zimmerman lecture. *JAMA Ophthalmol* 131, 462-9 (2013).
- 48. Meyer, Y., Bohlok, A., Hoppener, D., Galjart, B., Doukas, M., Grunhagen, D.J. et al.
  Histopathological growth patterns of resected non-colorectal, non-neuroendocrine
  liver metastases: a retrospective multicenter studyss. *Clin Exp Metastasis* (2022).
- 49. Fernandez Moro, C., Bozoky, B. & Gerling, M. Growth patterns of colorectal cancer
  liver metastases and their impact on prognosis: a systematic review. *BMJ Open Gastroenterol* 5, e000217 (2018).
- 1214 50. Kwapisz, D. Oligometastatic breast cancer. *Breast Cancer* **26**, 138-146 (2019).
- 121551.Tran, C.G., Sherman, S.K., Chandrasekharan, C. & Howe, J.R. Surgical Management of1216Neuroendocrine Tumor Liver Metastases. Surg Oncol Clin N Am **30**, 39-55 (2021).
- Teng, S., Li, Y.E., Yang, M., Qi, R., Huang, Y., Wang, Q. et al. Tissue-specific transcription
  reprogramming promotes liver metastasis of colorectal cancer. *Cell Res* **30**, 34-49
  (2020).
- 1220 53. Nielsen, K., Rolff, H.C., Eefsen, R.L. & Vainer, B. The morphological growth patterns of
  1221 colorectal liver metastases are prognostic for overall survival. *Mod Pathol* 27, 1641-8
  1222 (2014).
- 54. Eefsen, R.L., Vermeulen, P.B., Christensen, I.J., Laerum, O.D., Mogensen, M.B., Rolff,
  H.C. et al. Growth pattern of colorectal liver metastasis as a marker of recurrence risk. *Clin Exp Metastasis* 32, 369-81 (2015).
- 1226 55. Kuczynski, E.A., Yin, M., Bar-Zion, A., Lee, C.R., Butz, H., Man, S. et al. Co-option of Liver
  1227 Vessels and Not Sprouting Angiogenesis Drives Acquired Sorafenib Resistance in
  1228 Hepatocellular Carcinoma. J Natl Cancer Inst 108, (2016).
- 122956.Bridgeman, V.L., Vermeulen, P.B., Foo, S., Bilecz, A., Daley, F., Kostaras, E. et al. Vessel1230co-option is common in human lung metastases and mediates resistance to anti-1231angiogenic therapy in preclinical lung metastasis models. J Pathol 241, 362-374 (2017).
- 1232 57. Leenders, W.P., Kusters, B., Verrijp, K., Maass, C., Wesseling, P., Heerschap, A. et al.
  1233 Antiangiogenic therapy of cerebral melanoma metastases results in sustained tumor
  1234 progression via vessel co-option. *Clin Cancer Res* **10**, 6222-30 (2004).
- 123558.Martens, T., Laabs, Y., Gunther, H.S., Kemming, D., Zhu, Z., Witte, L. et al. Inhibition of1236glioblastoma growth in a highly invasive nude mouse model can be achieved by1237targeting epidermal growth factor receptor but not vascular endothelial growth factor1238receptor-2. Clin Cancer Res 14, 5447-58 (2008).
- 123959.Mentha, G., Terraz, S., Morel, P., Andres, A., Giostra, E., Roth, A. et al. Dangerous halo1240after neoadjuvant chemotherapy and two-step hepatectomy for colorectal liver1241metastases. Br J Surg **96**, 95-103 (2009).
- Rubbia-Brandt, L., Giostra, E., Brezault, C., Roth, A.D., Andres, A., Audard, V. et al.
  Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery. *Ann Oncol* 18, 299-304 (2007).
- 1246 61. Nierop, P.M., Hoppener, D.J., Buisman, F.E., van der Stok, E.P., Galjart, B.,
  1247 Balachandran, V.P. et al. Preoperative systemic chemotherapy alters the
  1248 histopathological growth patterns of colorectal liver metastases. *J Pathol Clin Res* 8,
  1249 48-64 (2022).

- Gomez Dorronsoro, M.L., Vera, R., Ortega, L., Plaza, C., Miquel, R., Garcia, M. et al.
  Recommendations of a group of experts for the pathological assessment of tumour
  regression of liver metastases of colorectal cancer and damage of non-tumour liver
  tissue after neoadjuvant therapy. *Clin Transl Oncol* **16**, 234-42 (2014).
- 1254 63. Powley, I.R., Patel, M., Miles, G., Pringle, H., Howells, L., Thomas, A. et al. Patient-1255 derived explants (PDEs) as a powerful preclinical platform for anti-cancer drug and 1256 biomarker discovery. *Br J Cancer* **122**, 735-744 (2020).
- 1257 64. Voabil, P., de Bruijn, M., Roelofsen, L.M., Hendriks, S.H., Brokamp, S., van den Braber,
  1258 M. et al. An ex vivo tumor fragment platform to dissect response to PD-1 blockade in
  1259 cancer. Nat Med 27, 1250-1261 (2021).
- Fornabaio, G., Barnhill, R.L., Lugassy, C., Bentolila, L.A., Cassoux, N., Roman-Roman, S.
  et al. Angiotropism and extravascular migratory metastasis in cutaneous and uveal
  melanoma progression in a zebrafish model. *Sci Rep* 8, 10448 (2018).
- 1263 66. Latacz, E., van Dam, P.J., Vanhove, C., Llado, L., Descamps, B., Ruiz, N. et al. Can medical
  imaging identify the histopathological growth patterns of liver metastases? *Semin*1265 *Cancer Biol* **71**, 33-41 (2021).
- 1266 67. Wei, S., Han, Y., Zeng, H., Ye, S., Cheng, J., Chai, F. et al. Radiomics diagnosed 1267 histopathological growth pattern in prediction of response and 1-year progression free 1268 survival for colorectal liver metastases patients treated with bevacizumab containing 1269 chemotherapy. *Eur J Radiol* **142**, 109863 (2021).
- 1270 68. Er, E.E., Valiente, M., Ganesh, K., Zou, Y., Agrawal, S., Hu, J. et al. Pericyte-like spreading
  1271 by disseminated cancer cells activates YAP and MRTF for metastatic colonization. *Nat*1272 *Cell Biol* **20**, 966-978 (2018).
- Suzuki, K., Tanaka, M., Watanabe, N., Saito, S., Nonaka, H. & Miyajima, A. p75
  Neurotrophin receptor is a marker for precursors of stellate cells and portal fibroblasts
  in mouse fetal liver. *Gastroenterology* 135, 270-281 e3 (2008).
- 1276 70. Wells, R.G. The portal fibroblast: not just a poor man's stellate cell. *Gastroenterology*1277 147, 41-7 (2014).
- Trim, N., Morgan, S., Evans, M., Issa, R., Fine, D., Afford, S. et al. Hepatic stellate cells
  express the low affinity nerve growth factor receptor p75 and undergo apoptosis in
  response to nerve growth factor stimulation. *Am J Pathol* **156**, 1235-43 (2000).
- 128172.Passino, M.A., Adams, R.A., Sikorski, S.L. & Akassoglou, K. Regulation of hepatic stellate1282cell differentiation by the neurotrophin receptor p75NTR. Science **315**, 1853-6 (2007).
- 1283 73. Kendall, T.J., Hennedige, S., Aucott, R.L., Hartland, S.N., Vernon, M.A., Benyon, R.C. et
  1284 al. p75 Neurotrophin receptor signaling regulates hepatic myofibroblast proliferation
  1285 and apoptosis in recovery from rodent liver fibrosis. *Hepatology* 49, 901-10 (2009).
- Aimaiti, Y., Jin, X., Shao, Y., Wang, W. & Li, D. Hepatic stellate cells regulate hepatic
  progenitor cells differentiation via the TGF-beta1/Jagged1 signaling axis. *J Cell Physiol* **234**, 9283-9296 (2019).
- 1289 75. Cassiman, D., Denef, C., Desmet, V.J. & Roskams, T. Human and rat hepatic stellate
  1290 cells express neurotrophins and neurotrophin receptors. *Hepatology* 33, 148-58
  1291 (2001).
- 1292 76. Vidal-Vanaclocha, F., Crende, O., Garcia de Durango, C., Herreros-Pomares, A., Lopez1293 Domenech, S., Gonzalez, A. et al. Liver prometastatic reaction: Stimulating factors and
  1294 responsive cancer phenotypes. *Semin Cancer Biol* **71**, 122-133 (2021).

medRxiv preprint doi: https://doi.org/10.1101/2022.04.07.22273504; this version posted April 10, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

- 1295 77. Ciner, A.T., Jones, K., Muschel, R.J. & Brodt, P. The unique immune microenvironment
  1296 of liver metastases: Challenges and opportunities. *Semin Cancer Biol* **71**, 143-156
  1297 (2021).
- 1298 78. Kurebayashi, Y., Kubota, N. & Sakamoto, M. Immune microenvironment of 1299 hepatocellular carcinoma, intrahepatic cholangiocarcinoma and liver metastasis of 1300 colorectal adenocarcinoma: Relationship with histopathological and molecular 1301 classifications. *Hepatol Res* **51**, 5-18 (2021).
- 1302 79. Bohlok, A., Duran Derijckere, I., Azema, H., Lucidi, V., Vankerckhove, S., Hendlisz, A. et
  1303 al. Clinico-metabolic characterization improves the prognostic value of histological
  1304 growth patterns in patients undergoing surgery for colorectal liver metastases. *J Surg*1305 *Oncol* 123, 1773-1783 (2021).
- 130680.Matsumoto, K., Yoshitomi, H., Rossant, J. & Zaret, K.S. Liver organogenesis promoted1307by endothelial cells prior to vascular function. Science **294**, 559-63 (2001).
- 1308 81. Crivellato, E., Nico, B. & Ribatti, D. Contribution of endothelial cells to organogenesis:
  1309 a modern reappraisal of an old Aristotelian concept. *J Anat* **211**, 415-27 (2007).
- 1310 82. Ding, B.S., Cao, Z., Lis, R., Nolan, D.J., Guo, P., Simons, M. et al. Divergent angiocrine
  1311 signals from vascular niche balance liver regeneration and fibrosis. *Nature* 505, 971312 102 (2014).
- 131383.Daniel, E. & Cleaver, O. Vascularizing organogenesis: Lessons from developmental1314biology and implications for regenerative medicine. Curr Top Dev Biol132, 177-2201315(2019).
- 131684.Muthuswamy, S.K. Self-organization in cancer: Implications for histopathology, cancer1317cell biology, and metastasis. Cancer Cell **39**, 443-446 (2021).
- 1318 85. Pezzella, F., Di Bacco, A., Andreola, S., Nicholson, A.G., Pastorino, U. & Harris, A.L.
  1319 Angiogenesis in primary lung cancer and lung secondaries. *Eur J Cancer* **32A**, 2494-500
  1320 (1996).
- 132186.Evidence for novel non-angiogenic pathway in breast-cancer metastasis. Breast Cancer1322Progression Working Party. Lancet **355**, 1787-8 (2000).
- 1323 87. Teuwen, L.A., De Rooij, L., Cuypers, A., Rohlenova, K., Dumas, S.J., Garcia-Caballero, M.
  1324 et al. Tumor vessel co-option probed by single-cell analysis. *Cell Rep* 35, 109253
  1325 (2021).
- 132688.Lee, J.C., Green, M.D., Huppert, L.A., Chow, C., Pierce, R.H. & Daud, A.I. The Liver-1327Immunity Nexus and Cancer Immunotherapy. Clin Cancer Res 28, 5-12 (2022).
- 1328 89. Garcia-Vicién, G., Mezheyeuski, A., Micke, P., Ruiz, N., Ruffinelli, J.C., Mils, K. et al.
  1329 Spatial Immunology in Liver Metastases from Colorectal Carcinoma according to the
  1330 Histologic Growth Pattern. *Cancers* 14, 689 (2022).
- 1331 90. Szczepanski, J.M., Mendiratta-Lala, M., Fang, J.M., Choi, W.T., Karamchandani, D.M. &
  1332 Westerhoff, M. Sinusoidal Growth Pattern of Hepatic Melanoma Metastasis:
  1333 Implications for Histopathologic Diagnosis. *Am J Surg Pathol* (2021).
- 1334 91. Li, W.H., Wang, S., Liu, Y., Wang, X.F., Wang, Y.F. & Chai, R.M. Differentiation of
  1335 histopathological growth patterns of colorectal liver metastases by MRI features.
  1336 *Quant Imaging Med Surg* 12, 608-617 (2022).
- de Ridder, J.A., Knijn, N., Wiering, B., de Wilt, J.H. & Nagtegaal, I.D. Lymphatic Invasion
  is an Independent Adverse Prognostic Factor in Patients with Colorectal Liver
  Metastasis. Ann Surg Oncol 22 Suppl 3, S638-45 (2015).

- 1340 93. Serrablo, A., Paliogiannis, P., Pulighe, F., Moro, S.S., Borrego-Estella, V., Attene, F. et
  1341 al. Impact of novel histopathological factors on the outcomes of liver surgery for
  1342 colorectal cancer metastases. *Eur J Surg Oncol* 42, 1268-77 (2016).
- 134394.Fonseca, G.M., de Mello, E.S., Faraj, S.F., Kruger, J.A.P., Coelho, F.F., Jeismann, V.B. et1344al. Prognostic significance of poorly differentiated clusters and tumor budding in1345colorectal liver metastases. J Surg Oncol 117, 1364-1375 (2018).
- 1346 95. Cremolini, C., Milione, M., Marmorino, F., Morano, F., Zucchelli, G., Mennitto, A. et al.
  1347 Differential histopathologic parameters in colorectal cancer liver metastases resected
  1348 after triplets plus bevacizumab or cetuximab: a pooled analysis of five prospective
  1349 trials. *Br J Cancer* **118**, 955-965 (2018).
- 1350 96. Falcao, D., Alexandrino, H., Caetano Oliveira, R., Martins, J., Ferreira, L., Martins, R. et
  1351 al. Histopathologic patterns as markers of prognosis in patients undergoing
  1352 hepatectomy for colorectal cancer liver metastases Pushing growth as an
  1353 independent risk factor for decreased survival. *Eur J Surg Oncol* 44, 1212-1219 (2018).
- 135497.Ao, T., Kajiwara, Y., Yonemura, K., Shinto, E., Mochizuki, S., Okamoto, K. et al.1355Prognostic significance of histological categorization of desmoplastic reaction in1356colorectal liver metastases. Virchows Arch **475**, 341-348 (2019).
- 1357 98. Zhang, Y., Luo, X., Lin, J., Fu, S., Feng, P., Su, H. et al. Gelsolin Promotes Cancer
  1358 Progression by Regulating Epithelial-Mesenchymal Transition in Hepatocellular
  1359 Carcinoma and Correlates with a Poor Prognosis. J Oncol 2020, 1980368 (2020).
- Baldin, P., Van den Eynde, M., Mlecnik, B., Bindea, G., Beniuga, G., Carrasco, J. et al.
  Prognostic assessment of resected colorectal liver metastases integrating pathological
  features, RAS mutation and Immunoscore. *J Pathol Clin Res* 7, 27-41 (2021).
- 1363 100. Temido, M.J., Caetano Oliveira, R., Martins, R., Serodio, M., Costa, B., Carvalho, C. et
  1364 al. Prognostic Factors After Hepatectomy for Gastric Adenocarcinoma Liver
  1365 Metastases: Desmoplastic Growth Pattern as the Key to Improved Overall Survival.
  1366 *Cancer Manag Res* 12, 11689-11699 (2020).
- 1367 101. Jayme, V.R., Fonseca, G.M., Amaral, I.M.A., Coelho, F.F., Kruger, J.A.P., Jeismann, V.B.
  1368 et al. Infiltrative Tumor Borders in Colorectal Liver Metastasis: Should We Enlarge
  1369 Margin Size? Ann Surg Oncol 28, 7636-7646 (2021).
- 1370 102. Zhang, Y.L., He, H.J., Cheng, J. & Shen, D.H. [Value of histopathological growth pattern
  1371 in predicting 3-year progression free survival after operation in patients with liver
  1372 metastasis of colorectal cancer]. *Zhonghua Bing Li Xue Za Zhi* 50, 26-31 (2021).
- 1373 103. Meyer, Y.M., Beumer, B.R., Hoppener, D.J., Nierop, P.M.H., Doukas, M., de Wilde, R.F.
  1374 et al. Histopathological growth patterns modify the prognostic impact of microvascular
  1375 invasion in non-cirrhotic hepatocellular carcinoma. *HPB (Oxford)* (2021).
- 1376 104. Vles, M.D., Hoppener, D.J., Galjart, B., Moelker, A., Vermeulen, P.B., Grunhagen, D.J.
  1377 et al. Local tumour control after radiofrequency or microwave ablation for colorectal
  1378 liver metastases in relation to histopathological growth patterns. *HPB (Oxford)* (2022).
- 1379 105. Ceausu, A.R., Ciolofan, A., Cimpean, A.M., Magheti, A., Mederle, O. & Raica, M. The
  1380 Mesenchymal-Epithelial and Epithelial-Mesenchymal Cellular Plasticity of Liver
  1381 Metastases with Digestive Origin. *Anticancer Res* 38, 811-816 (2018).
- 1382106.Lazaris, A., Amri, A., Petrillo, S.K., Zoroquiain, P., Ibrahim, N., Salman, A. et al.1383Vascularization of colorectal carcinoma liver metastasis: insight into stratification of1384patients for anti-angiogenic therapies. J Pathol Clin Res 4, 184-192 (2018).
- 1385107.Wu, J.B., Sarmiento, A.L., Fiset, P.O., Lazaris, A., Metrakos, P., Petrillo, S. et al.1386Histologic features and genomic alterations of primary colorectal adenocarcinoma

1387 predict growth patterns of liver metastasis. World J Gastroenterol 25, 3408-3425 1388 (2019). 1389 108. Blank, A., Schenker, C., Dawson, H., Beldi, G., Zlobec, I. & Lugli, A. Evaluation of Tumor 1390 Budding in Primary Colorectal Cancer and Corresponding Liver Metastases Based on 1391 H&E and Pancytokeratin Staining. Front Med (Lausanne) 6, 247 (2019). 1392 109. Palmieri, V., Lazaris, A., Mayer, T.Z., Petrillo, S.K., Alamri, H., Rada, M. et al. Neutrophils 1393 expressing lysyl oxidase-like 4 protein are present in colorectal cancer liver metastases 1394 resistant to anti-angiogenic therapy. J Pathol 251, 213-223 (2020). 1395 Ao, T., Kajiwara, Y., Yonemura, K., Shinto, E., Mochizuki, S., Okamoto, K. et al. 110. 1396 Morphological consistency of desmoplastic reactions between the primary colorectal 1397 cancer lesion and associated metastatic lesions. Virchows Arch 477, 47-55 (2020). 1398 111. Rada, M., Kapelanski-Lamoureux, A., Petrillo, S., Tabaries, S., Siegel, P., Reynolds, A.R. 1399 et al. Runt related transcription factor-1 plays a central role in vessel co-option of 1400 colorectal cancer liver metastases. Commun Biol 4, 950 (2021). 1401 112. Burren, S., Reche, K., Blank, A., Galvan, J.A., Dawson, H., Berger, M.D. et al. RHAMM in 1402 liver metastases of stage IV colorectal cancer with mismatch-repair proficient status 1403 correlates with tumor budding, cytotoxic T-cells and PD-1/PD-L1. Pathol Res Pract 223, 1404 153486 (2021). 1405 Donnem, T., Reynolds, A.R., Kuczynski, E.A., Gatter, K., Vermeulen, P.B., Kerbel, R.S. et 113. 1406 al. Non-angiogenic tumours and their influence on cancer biology. Nat Rev Cancer 18, 1407 323-336 (2018). 1408 114. Baldin, P., Van den Eynde, M., Hubert, C., Jouret-Mourin, A. & Komuta, M. The role of 1409 the pathologist and clinical implications in colorectal liver metastasis. Acta 1410 Gastroenterol Belg 81, 419-426 (2018). 1411 Kuczynski, E.A., Vermeulen, P.B., Pezzella, F., Kerbel, R.S. & Reynolds, A.R. Vessel co-115. 1412 option in cancer. Nat Rev Clin Oncol 16, 469-493 (2019). 1413 Oliveira, R.C., Alexandrino, H., Cipriano, M.A. & Tralhao, J.G. Liver Metastases and 116. Histological Growth Patterns: Biological Behavior and Potential Clinical Implications-1414 1415 Another Path to Individualized Medicine? J Oncol 2019, 6280347 (2019). 1416 117. Kuczynski, E.A. & Reynolds, A.R. Vessel co-option and resistance to anti-angiogenic 1417 therapy. Angiogenesis 23, 55-74 (2020). 1418 Oliveira, R.C., Alexandrino, H., Cipriano, M.A., Alves, F.C. & Tralhao, J.G. Predicting liver 118. 1419 metastases growth patterns: Current status and future possibilities. Semin Cancer Biol 1420 71, 42-51 (2021). 1421 Rigamonti, A., Feuerhake, F., Donadon, M., Locati, M. & Marchesi, F. Histopathological 119. and Immune Prognostic Factors in Colo-Rectal Liver Metastases. Cancers (Basel) 13, 1422 1423 (2021). 1424 120. Garcia-Vicien, G., Mezheyeuski, A., Banuls, M., Ruiz-Roig, N. & Mollevi, D.G. The Tumor 1425 Microenvironment in Liver Metastases from Colorectal Carcinoma in the Context of 1426 the Histologic Growth Patterns. Int J Mol Sci 22, (2021). 1427 121. Haas, G., Fan, S., Ghadimi, M., De Oliveira, T. & Conradi, L.C. Different Forms of Tumor 1428 Vascularization and Their Clinical Implications Focusing on Vessel Co-option in 1429 Colorectal Cancer Liver Metastases. Front Cell Dev Biol 9, 612774 (2021). 1430 122. Rompianesi, G., Pegoraro, F., Ceresa, C.D., Montalti, R. & Troisi, R.I. Artificial 1431 intelligence in the diagnosis and management of colorectal cancer liver metastases. 1432 World J Gastroenterol 28, 108-122 (2022).

- 1433 123. Paku, S. & Lapis, K. Morphological aspects of angiogenesis in experimental liver 1434 metastases. *Am J Pathol* **143**, 926-36 (1993).
- 1435 124. Vidal-Vanaclocha, F. The prometastatic microenvironment of the liver. *Cancer* 1436 *Microenviron* 1, 113-29 (2008).
- 1437 125. Barsky, S.H., Doberneck, S.A., Sternlicht, M.D., Grossman, D.A. & Love, S.M. 'Revertant'
  1438 DCIS in human axillary breast carcinoma metastases. *J Pathol* 183, 188-94 (1997).
- 1439 126. Schuppan, D. & Kim, Y.O. Evolving therapies for liver fibrosis. *J Clin Invest* **123**, 1887-1440 901 (2013).
- 1441 127. Dezso, K., Papp, V., Bugyik, E., Hegyesi, H., Safrany, G., Bodor, C. et al. Structural 1442 analysis of oval-cell-mediated liver regeneration in rats. *Hepatology* **56**, 1457-67 1443 (2012).
- 1444

First author	Reference	Methodology	Tumour type	Main findings
Animal models				
Alzubi M.A.	Clin Exp Metastasis 2019 <sup>11</sup>	Portal vein injection of cancer cells of PDX mammary tumours of 14 patients in NOD <i>scid gamma</i> mice.	Breast cancer	HGPs could be assessed in six PDX models: replacement, desmoplastic and pushing HGPs were identified.
Piquet L.	Cancers 2019 <sup>12</sup>	Co-inoculation into the spleen of human primary hepatic stellate cells and 5 human uveal melanoma cell lines in NOD <i>scid gamma</i> or NOD CRISPR <i>Prkdc Il2r gamma</i> mice.	Uveal Melanoma	Desmoplastic, replacement and mixed liver metastases were observed. The HGP was not altered by co- inoculation of stellate cells (figure 5A and table 2 of the publication)
Vlachogiannis G.	Science 2018 <sup>13</sup>	A biobank of patient-derived organoids and xenografts was constructed (110 fresh biopsies from 71 patients enrolled in four prospective phase 1/2 clinical trials were processed)	Colorectal and gastro- oesophageal cancer	A predominance of replacement HGP was observed in xenografts from resistant patient, whereas tumours established from sensitive patient showed a prevalence of desmoplastic and pushing HGPs.
Ibrahim N.S.	Cancers 2020 <sup>14</sup>	Intra-splenic injection of MC-38 mouse CRC cell line in inducible Ang1 knock-out C57BL/6 mice.	Colorectal cancer	Replacement HGP liver metastases in control mice and desmoplastic HGP liver metastases in Ang1 knock-out condition.

Masaki S.	Int J Exp Pathol 2020 <sup>15</sup>	Fatty liver conditions were induced in BALB/c mice. CT26 cells were injected into the liver.	Colorectal cancer	Tumours in control mice showed encapsulated growth patterns, while tumours in fatty livers showed invasive growth
Tabariès S.	Commun Biol 2021 <sup>16</sup>	Intrahepatic transplantation of patient liver metastasis tissue fragments in Scid-beige mice. Expression profiles of claudins were compared between dHGP and rHGP in PDXs and in liver metastases of patients.	Colorectal cancer	without encapsulation. Liver metastases in mice express the HGP of the liver metastases of the patient-donor. Claudin-2 in patient-derived extracellular vesicles may be a marker of rHGP.
Bartlett A.	Cancers 2021 <sup>17</sup>	Portal vein injection of D2OR, a low metastatic mouse mammary tumour cell line in nulliparous BALB/c immune competent mice and weaning- induced liver involution mice.	Breast cancer	The post-weaning liver is in an immune suppressed state with increased tumour incidence and multiplicity. A greater diversity of HGPs was noted in the post- weaning mice, consistent with the liver microenvironment dictating tumour histology.
Immune contex	<b>ture</b> (also: Watanabe K. in 'He	GP scoring methodology' section)		
Stremitzer S.	Br J Cancer 2020 <sup>2</sup>	The immune phenotype of liver metastases was scored based on the distribution of CD8- immunostained cytotoxic T-lymphocytes as 'desert', 'excluded' (together 'non-inflamed') and 'inflamed' (81 patients). Bevacizumab-based chemotherapy was administered to all patients before partial liver resection.	Colorectal cancer	The inflamed immune phenotype was associated with the desmoplastic HGP and was associated with improved RFS and OS in univariable, not multivariable analyses.

Liang J.	Cancer Immunol Immunother 2020 <sup>3</sup>	The immunoscore was calculated according to the densities of immunostained CD3 + and CD8 + cells (166 patients). One immunoscore per patient was calculated based on assessments in the tumour centre and in the invasive margin.	Colorectal cancer	A high immunoscore was more often encountered in liver metastases with a desmoplastic HGP than with a replacement HGP. A combined risk score (HGP, immunoscore and clinical risk score) was developed and a 90% 5-year OS rate was observed for patients in the low-risk group (30% of the patients).
Höppener D.J.	Br J Cancer 2020 <sup>4</sup>	The immune contexture of resected liver metastases was analysed in 3 cohort of chemo- naive patients (117, 34 and 79 patients, respectively) with immunohistochemistry (semi- quantitative grading, quantitative digital image analysis) and flow cytometry. The 100% desmoplastic HGP cut off was applied.	Colorectal cancer	An increased immune infiltrate is associated with the desmoplastic HGP, both surrounding and in the metastases. Intra-epithelial CD8+ cells were also increased in the desmoplastic HGP.
Messaoudi N.	Br J Cancer. 2022 <sup>6</sup>	Immunohistochemistry and automated quantitative analysis on tissue microarray (176 patients) of CD3, MHC-I and CD73. Liver metastases were categorized according to the dominant HGP and according to the 100% desmoplastic HGP cut off.	Colorectal cancer	Desmoplastic liver metastases were more infiltrated by CD3 + cells, expressed lower levels of MHC-I, and similar levels of CD73. Elevated CD73 expression was associated with a worse outcome of patients with desmoplastic HGP liver metastases. Low MHC-I expression in patients with

				replacement-type metastases improved outcome.
Garcia-Vicién G	Cancers 2022 <sup>89</sup>	The spatial distribution of lymphocytic infiltrates in CRC liver metastases was explored in the context of the HGPs by multiplex immunofluorescence staining and digital image analysis in a cohort of 22 resected metastases without pre-surgery chemotherapy. HGPs were scored following the previous guidelines. The desmoplastic rim was excluded from the invasive margin for lymphocyte counting ('Measure B').	Colorectal cancer	The number of CD8-positive cells at the invasive margin was independent of the HGP. In non- desmoplastic metastases, the cytotoxic T cells did not enter the tumour cell nests and CD4- positive cells were more abundant at the invasive margin than in desmoplastic lesions.
HGP scoring me	thodology			
Höppener D.J.	Clin Exp Metastasis 2019 <sup>39</sup>	Within and between metastasis HGP concordance was analysed in 363 patients with 2 or more resected liver metastases. The association of diagnostic accuracy with number of sections and number of metastases evaluated was determined. Interobserver agreement of HGP scoring was assessed after training. The 100% desmoplastic HGP cut off was applied.	Colorectal cancer	Within metastasis concordance ranged from 93% to 96%. Between metastasis concordance was 90%. Diagnostic accuracy peaked at two sections and two metastases. After two training sessions, interobserver agreement had a kappa-value of more than 0.9.
Watanabe K.	Cancer Med 2020 <sup>5</sup>	Biopsies of liver metastases of 107 patients with pancreatic cancer (21- or 18-gauge needle) were used for HGP assessment. The dominant HGP was determined. If a HGP was present in more than	Pancreatic cancer	Of 279 patients, 107 patients had a biopsy that contained the tumour-liver interface. HGP had a homogenous expression in 13/14 patients. Disease control

		80% of the interface, the HGP was called		rate as well as overall survival
		'homogenous' (analysis in 14 patients).		rate were lower in the
				replacement HGP group. The
				replacement HGP biopsies
				showed less inflammation (H&E)
				and contained less CD8 + cells
				than the other biopsies.
Szczepanski J.	Am J Surg Pathol	The HGP was scored in biopsies of liver	Melanoma	In 8/30 (4 ocular, 4 skin, 27%)
	2021 <sup>90</sup>	metastases of melanoma (n=30; 22 skin		melanoma liver metastases, a
		melanomas; 6 ocular melanomas; 2 unknown		sinusoidal HGP was seen. In
		origin).		none of the 96 metastases of
				breast, colon, pancreaticobiliary
				cancer and neuroendocrine
				tumours this HGP was
				encountered.
Medical imagin	g			
Gulia S.	BMJ Case Rep 2016 <sup>7</sup>	A case report of a radiographically occult liver	Breast cancer	A biopsy established the
		metastasis leading to liver failure is presented.		diagnosis of a liver metastasis
				with intra-sinusoidal growth
				pattern.
Cheng J.	Ann Surg Oncol 2019 <sup>8</sup>	A radiomic algorithm was developed to identify	Colorectal	The dominant HGP of the liver
0		the dominant HGPs of liver metastases by	cancer	metastases could be predicted
		computed tomography (CT) imaging. Pre- and		with 65% sensitivity and 92%
		post-contrast as well as arterial and portal venous		specificity (accuracy of 77%). A
		phase images (ROI: tumour-liver interface)		decisive feature used by the
		contributed to the algorithm (126 metastases of		algorithm is the presence
		94 chemo-naive patients - variety of scanners but		(desmoplastic) or absence
		standardized acquisition protocol and use of		(replacement) of peripheral rim
		contrast agent).		enhancement in the portal-

				venous phase. No clinical or qualitative image data were used by the algorithm.
Han Y.	Front Oncol 2020 <sup>9</sup>	A radiomic algorithm was developed to identify the dominant HGP of liver metastases by magnetic resonance imaging (MRI). (ROI: tumour- liver interface (TLI) - 182 liver metastases (107 chemo-naive patients))	Colorectal cancer	The radiomic algorithm that best predicted the dominant HGP was based on quantitative features extracted from the TLI combined with clinical data and a qualitative image feature ('lobular margin') (79% accuracy, 100% sensitivity, 35% specificity). The desmoplastic HGP had more heterogeneous radiomic features than the replacement HGP.
Starmans M.P.A.	Clin Exp Metastasis 2021 <sup>10</sup>	A radiomic algorithm was developed to distinguish liver metastases with 100% desmoplastic HGP from liver metastases with 100% replacement HGP by CT imaging (76 chemo-naive patients with 93 metastases).	Colorectal cancer	Despite the use of only portal venous phase contrast- enhanced images, variations in lesion segmentation and acquisition protocols, accuracy was 65%, sensitivity 72% and specificity 58%.
Wei S.	Eur J Radiol 2021 <sup>67</sup>	The CT image-based radiomics algorithm to identify the dominant HGP developed in Cheng et al. (2019) was used to predict response to bevacizumab-chemotherapy in 119 patients (346 lesions) with unresectable CRC liver metastases.	Colorectal cancer	AUC for predicting early response was 0.72. The radiomics algorithm-derived HGP was the only independent predictor of 1-year PFS.

Li W.H.	Quant Imaging Med	MRI features were used to predict the dominant	Colorectal	AUC for predicting the dominant
	Surg 2022 <sup>91</sup>	HGP in 53 chemo-naïve patients.	cancer	HGP based on diameter
				difference between pre- and
				post-contrast images and rim
				enhancement was 0.83.
HGP as biomark	er (HGP assessment not	according to guidelines, according to guidelines with	dominant HGP as a	categories and according to
guidelines with	100% desmoplastic HGP	versus any percentage of replacement as categories)		
de Ridder	Ann Surg Onc 2015 <sup>92</sup>	The presence/absence of a fibrous capsule was	Colorectal	In univariable but not
J.A.M.		scored on H&E sections of resected liver	cancer	multivariable analysis, the
		metastases of 124 chemo-naive patients with a		presence of a fibrous capsule
		solitary metastasis. The proportion of the		was associated with improved
		tumour-liver interface with/without capsule was		OS (109 months versus 57
		not reported.		months).
Serrablo A.	Eur J Surg Oncol	The presence/absence of a fibrous capsule with a	Colorectal	The capsule was present in 17%
	2016 <sup>93</sup>	thickness of at least 0,5mm in the entire tumour-	cancer	of the patients, independent of
		liver interface was assessed on H&E sections (147		pre-surgery treatment status,
		patients: 74/147 with pre-surgery systemic		and did not have an impact on
		treatment)		survival.
Fonseca G.M.	J Surg Oncol 2018 <sup>94</sup>	Tumour border pattern was scored according to	Colorectal	Both absence of a fibrous
		the Jass classification (infiltrative, expansive). A	cancer	capsule (75% of patients) and
		fibrous capsule was scored as being absent or		infiltrative growth (74% of
		present. A single tissue block of the largest		patients) were associated with
		metastasis was selected for each patient (229		shorter OS and DFS in
		patients, all with peri-operative systemic		multivariable and/or univariable
		treatment).		analyses. Both parameters were
				also associated with hepatic
				recurrence.

Cremolini C.	Br J Cancer 2018 <sup>95</sup>	HGPs were scored according to the international	Colorectal	There was no effect of HGP on
		guidelines. The effect of the HGPs on US and DFS	cancer	OS or DFS. An Important remark
		was investigated in a conort of patients with liver		is that the proportion of
		metastases and with chemotherapy combined		patients with liver metastases
		with either bevacizumab or cetuximab prior to		with a dominant pushing HGP
		surgery (159 patients).		was much higher than reported
				in most other studies (41%).
Falcao D.	Eur J Surg Oncol	HGPs of liver metastases were scored in 110	Colorectal	The pushing HGP was
	2018 <sup>96</sup>	patients of which 52 patients received pre-	cancer	independently associated with
		surgery chemotherapy. A mixed HGP was		worse OS and DFS. An important
		identified when more than one HGP was		remark is that the proportion of
		expressed by the metastases and each HGP was		patients with liver metastases
		present in at least 25% of the interface.		with a pushing HGP was much
				higher than reported in most
				other studies (30%).
Barnhill R.	J Pathol Clin Res	The dominant HGP was scored according to the	Uveal	Dominant replacement HGP
	2018 <sup>44</sup>	international guidelines. Gene alterations were	melanoma	metastases were present in 73%
		assessed by array CGH (41 liver metastases		of patients (27%: desmoplastic
		originating from 41 patients).		HGP). On multivariate analysis,
				only HGP and resection status
				predicted OS (HR of 6.5 for
				replacement HGP).
Galjart B.	Angiogenesis 2019 <sup>18</sup>	HGPs were scored according to the international	Colorectal	About 20% of the patients with
		guidelines but patients were categorized as	cancer	surgical resection of CRC liver
		having 100% desmoplastic (dHGP) liver		metastases ended up in 100%
		metastases or not (non-dHGP) (732 patients of		dHGP group. This was
		which 367 chemo-naive before surgery)		associated with an outstanding
				outcome, especially in the
				chemo-naïve group (78% with at
				least 5 years OS)

Nieren D.M.L	Clip Exp Matastasia	LICD was seared as 100% dosmanlastic (dUCD)	Coloratel	Dationts with dUCD at first
Merop P.W.H.	CIIII EXP IVIETASTASIS		Colorectal	
	201923	versus non-dHGP in 690 patients free of disease	cancer	partial hepatectomy were more
		after first resection of liver metastases of which		often treated with curative
		492 developed recurrent disease.		intent and more often had
				recurrences salvageable by local
				treatment modalities.
Ao T	Virchows Arch 2019 <sup>97</sup>	The desmoplastic reaction in and around liver	Colorectal	The type of desmoplastic
		metastases was scored as mature/intermediate	cancer	reaction was independently
		(mature collagen fibers and keloid-like collagen)		associated with outcome with
		and immature (myxoid collagen present) in 204		65% 5-years OS in the mature
		patients with resected liver metastases of which		/intermediate group versus 35%
		78 had received preoperative chemotherapy		in the immature group.
Barnhill R	J Pathol Clin Res	HGP was scored as 100% desmoplastic (dHGP)	Cutaneous	Multivariate analysis
	2020 <sup>45</sup>	versus 'any % of replacement' (any rHGP) (43 liver	melanoma	demonstrated that only HGP
		metastases from 42 patients).		was associated with OS after
				resection of the liver metastases
				(HR for 'any rHGP' of 3.8).
Zhang Y	J Oncol 2020 <sup>98</sup>	Encapsulation of hepatocellular carcinoma was	Hepatocellular	In multivariate analyses, the
Ű		assessed in 188 patients (method not specified).	carcinoma	presence of a capsule was
				associated with improved DFS
				and OS (HR of 0.60 and 0.51
				respectively).
Buisman F.F.	Clin Exp Metastasis	HGP was scored as 100% desmoplastic (dHGP)	Colorectal	Adjuvant chemotherapy
Daloman i El	2020 <sup>25</sup>	versus non-dHGP in resected liver metastases of	cancer	improved OS and DES only in
	2020	1236 natients of whom 656 received pre-	cancer	natients with non-dHGP liver
		operative chemotherapy		metastases who did not receive
				pre-operative chemotherapy
				(HP of 0.52 and 0.71
				respectively)

Baldin P.	J Pathol Clin Res 2021 <sup>99</sup>	A pathological score (combining 'more than 3 lesions', 'R1 positive margin', 'non-100% desmoplastic HGP', 'steatohepatitis') and the consensus Immunoscore were tested for effect on outcome in 221 patients (85% received pre- operative chemotherapy; 582 liver metastases). Remark: per patient HGP used for outcome analysis was determined by selecting the 'worst' metastasis: pure replacement or mixed HGP.	Colorectal cancer	Non-desmoplastic HGP predicted shorter time to relapse in univariate and multivariate analyses (HRs 1,84 en 1,75, respectively). Patients with a favourable pathological score and a high immunoscore had the lowest risk of relapse (about 60% 5 yrs survival).
Temido M.	Cancer Management and Research 2020 <sup>100</sup>	HGP was scored as dHGP (100%) versus any % of non-desmoplastic growth (17 patients).	Gastric cancer	dHGP was independently associated with improved OS (HR=0.1, p=0.02).
Bohlok A.	NPJ Breast Cancer 2020 <sup>42</sup>	HGP was scored as 100% replacement (rHGP) versus 'any % of desmoplastic (any dHGP) (36 patients (11 patients with multiple metastases)).	Breast cancer	Any dHGP was independently associated with better PFS after liver surgery when compared with rHGP (HR=0.24, p = 0.009). All patients with rHGP relapsed within 20 months after liver surgery.
Jayme V.R.	Ann Surg Oncol 2021 <sup>101</sup>	Tumour growth pattern of CRC liver metastases was defined as 'infiltrative' or 'pushing', according to Jass J.R. in 182 patients who underwent partial hepatectomy.	Colorectal cancer	Patients with infiltrative liver metastases (68% of patients) had worse OS and DFS, independent of surgical margin width.
Zhang Y.L.	Zhonghua Bing Li Xue Za Zhi 2021 <sup>102</sup>	The dominant HGP was scored according to the international guidelines in 80 patients with partial hepatectomy.	Colorectal cancer	The 3-year PFS of patients with dHGP liver metastases (54%) was significantly longer compared with rHGP (40%).

				HGP was an independent prognostic factor for survival.
Höppener D.J.	JNCI Cancer Spectr 2021 <sup>19</sup>	HGP was scored as dHGP (100%) versus any % of non-desmoplastic growth in international multicentre retrospective validation study (780 patients treated by liver surgery).	Colorectal cancer	The association of dHGP and good outcome was confirmed, independent of <i>KRAS</i> and <i>BRAF</i> status. The presence, not the extent, of a non-desmoplastic component, negatively impacts outcome.
Meyer J.M.	HPB (Oxford) 2021 <sup>103</sup>	In a cohort of 155 patients with resected non- cirrhotic hepatocellular carcinoma (HCC), HGP (100% desmoplastic versus any % of replacement) and microvascular invasion (MVI) were scored.	Hepatocellular carcinoma	Both non-dHGP and MVI were associated with worse outcome (OS, DFS) in multivariate analyses. For OS, there was effect modification between HGP and MVI, with patients with MVI and non-dHGP having the shortest survival time.
Vles M-J	HPB (Oxford) 2022 <sup>104</sup>	In a cohort of 221 patients who received simultaneous resection and ablation as a first treatment for liver metastases, HGP was scored in the resected metastases (100% desmoplastic versus any % of replacement (non-desmoplastic)).	Colorectal cancer	A non-desmoplastic HGP of the resected metastases independently predicted local tumour progression adjacent to the post-ablation zone (HR of 1.55 (p = 0.04)).
Meyer Y	Clin Exp Metastasis 2022 <sup>48</sup>	In a cohort of 132 patients with liver metastases from 25 different tumour types, HGP was scored (100% desmoplastic versus any % of replacement (non-desmoplastic)).	Non-colorectal, non- neuroendocrine tumours	The HGPs could be identified in all tumour types. A desmoplastic HGP was associated with favourable outcome (OS: HR of 0.51 (p =

				0.04); RFS: HR of 0.38 (p < 0.01)) upon multivariable analysis.
HGP and tumou	r biology			
Grossniklaus H.E.	Hum Pathol 2016 <sup>46</sup>	Post-mortem histological liver analysis of 15 patients who died from metastatic uveal melanoma. Immunofluorescence staining for MMP9 and VEGF.	Uveal melanoma	Cancer cells in the 'infiltrative' growth pattern (resembling replacement HGP) do not express VEGF and MMP9, while cancer cells in the 'nodular' growth pattern (resembling pushing & desmoplastic HGP) express VEGF and MMP9. Hypothesis: infiltrative metastases originate in the sinusoidal space while nodular metastases originate in the portal tracts.
Ceausu A.R.	Anticancer Res 2018 <sup>105</sup>	Double immunostaining for keratin8/18-vimentin and for E-cadherin-vimentin. The mesenchymal/epithelial hybrid phenotype cells were quantified (25 patients).	Colorectal, pancreatic and gastric cancer	All the liver metastases of pancreatic cancer had a replacement HGP; all the liver metastasis of gastric cancer had a pushing HGP; CRC liver metastases exhibited all 3 HGPs. Replacement and pushing type metastases have a higher amount of cancer cells with EMT phenotype than desmoplastic metastases.

Lazaris A.	J Pathol Clin Res 2018 <sup>106</sup>	Immunohistochemistry (CD31 and CD34/Ki67; VEGF) to quantify microvessel density and blood vessels with endothelial cell proliferation (50 liver metastases of 50 patients). The dominant HGP was determined.	Colorectal cancer	Metastases with a desmoplastic HGP have a lower microvessel density than metastases with a replacement HGP. Endothelial cell proliferation was much higher in desmoplastic liver metastases unless systemic treatment was given prior to surgery. In chemo-naïve patients, there was no difference in VEGF-expression levels between both HGPs.
Wu J.B.	World J Gastroenterol 2019 <sup>107</sup>	HGP was scored in the liver metastases and in the primary tumours (liver metastases from 29 patients with matching primary tumours). Additional histological parameters were assessed in the primary tumours. Whole exome sequencing (WES) was performed on 5 cases.	Colorectal cancer	15 cases with desmoplastic HGP and 14 cases with replacement HGP. High tumour budding score, absence of Crohn's disease-like inflammatory response and infiltrating HGP of the primary tumour were associated with replacement HGP. Small cohort with WES results.
Nierop P.M.H.	HPB Oxford 2019 <sup>24</sup>	All available H&E-stained sections of all resected CRC liver metastases from 1302 patients were used for HGP scoring (100% desmoplastic versus any% of replacement). Hepatic resection margins were evaluated as positive or negative.	Colorectal cancer	Upon multivariate analyses, a non-desmoplastic HGP and number of metastases was associated with increased risk of positive resection margins.

Blank A.	Front Med 2019 <sup>108</sup>	Tissue microarray of 81 primary tumours and 139 corresponding liver metastases. Tumour budding was scored in primary CRCs and in liver metastases (intra- and peri-metastatic) on H&E and pan-cytokeratin-stained section. The association of budding in the primary tumour and	Colorectal cancer	Assessment of budding only reliable in desmoplastic liver metastases without extensive ductular reaction. No clear association of budding in primary CRC and metastases.
Palmieri V.	J Pathol 2020 <sup>109</sup>	RNA sequencing (16 liver metastases was not analysed. RNA sequencing (16 liver metastases from chemo-naive patients: 7 predominant replacement HGP and 9 desmoplastic) and immunohistochemistry (20 liver metastases from chemo-naive patients: 10 replacement and 10 desmonlastic cases)	Colorectal cancer	<i>CXCL6</i> and <i>LOXL4</i> upregulated in replacement HGP metastases. LOXL4 protein is expressed in neutrophils at the tumour-liver interface of these metastases.
Ao T.	Virchows Archiv 2020 <sup>110</sup>	The association of the type of desmoplastic reaction (mature, intermediate, immature) in the primary tumour and the liver metastases was investigated in 45 patients with synchronous liver metastases.	Colorectal cancer	A significant association was reported (r=0.40, P = 0.0069).
Bohlok A.	J Surg Oncol 2021 <sup>79</sup>	The metabolic Clinical Risk Score (mCRS), which includes FDG-PET as a metabolic parameter, was compared with the HGP of liver metastases and the prognostic value of combining mCRS and HGP was assessed in 108 patients.	Colorectal cancer	Liver metastases with a 100% desmoplastic HGP had a significantly lower glucose- uptake (metabolic activity) than non-desmoplastic liver metastases. A low mCRS was associated with improved outcome in patients with dHGP liver metastases.

Rada M.	Commun Biol 2021 <sup>111</sup>	Gene expression analyses and subsequent validation by immunohistochemistry in clinical samples of CRC liver metastases. Functional validation by targeted knock-down in CRC cancer cell lines and by using animal models.	Colorectal cancer	RUNX1 overexpression was shown to play a central in vessel co-option during replacement growth by inducing cancer cell motility and EMT. TSP1 and TGFbeta1 are involved in this process.
Burren S.	Pathol Res Pract 2021 <sup>112</sup>	In a cohort of 76 patients with mismatch repair proficient CRC liver metastases, HGP and peripheral and central budding were scored.	Colorectal cancer	Liver metastases with a replacement HGP more often show budding in their centre than desmoplastic metastases.
Nierop P.M.H.	J Pathol Clin Res 2021 <sup>61</sup>	In 3 cohorts of patients (n=877, 1203 and 70) the effect on pre-surgery chemotherapy on the HGP was assessed. The cohort of 70 patients belongs to a randomized clinical study.	Colorectal cancer	On average, the presence of a desmoplastic HGP increased with a factor of 1.5 when chemotherapy was administered before surgery. This was confirmed in the randomized study. The biology of the 'converted' metastases remains unclear.
Review manuscripts				
van Dam P-J.	Semin Cancer Biol 2018 <sup>32</sup>	Key differentiating histopathological characteristics of the HGPs and their impact on tumour biology are described. The review sums up arguments to support the hypothesis that the HGPs of liver metastasis have distinct cancer immune set-points and, thus, might affect clinical management strategies when immunomodulatory treatment is considered.		

Donnem T.	Nat Rev Cancer 2018 <sup>113</sup>	The discovery of non-angiogenic, vessel co-opting tumour growth is described as well as the biology of this means of vascularization and the implications for cancer treatment. The replacement HGP of liver metastases is discussed as one of the examples of non-angiogenic growth described in human studies.
Fernández Moro C.	BMJ Open Gastro 2018 <sup>49</sup>	This review has identified all studies up to December 2017 that reported the HGPs in patients with liver metastatic CRC, the relative frequencies of these HGPs, and the association with outcome. In 14 out of 17 cohorts, a significant favourable outcome was reported for patients with desmoplastic liver metastases. In 8 out of 12 cohorts, a significantly unfavourable outcome for patients with replacement-type liver metastases was found. The authors found no studies that reported an opposite association between HGP and outcome.
Baldin P.	Acta Gastroenterol Belg 2018 <sup>114</sup>	The review summarizes prognostic/predictive histopathological and molecular parameters for patients with liver metastatic colorectal cancer, the HGPs being one of these parameters. The authors argue for the integration of HGP in the pathology report.
Kuczynski E.A.	Nat Rev Clin Oncol 2019 <sup>115</sup>	Evidence that tumours located in numerous organs can use vessel co-option as a mechanism of tumour vascularization is described, the liver with the replacement HGP of metastases being one of the highlighted organs. Molecular mechanisms and implications for patients are also discussed.
Caetano Oliveira R.	J Oncol 2019 <sup>116</sup>	The prognostic significance, the biology and the therapeutic implications of the HGPs of CRC liver metastases are discussed. The authors propose to include the HGPs in the pathology report of resection of hepatic metastases.
Kuczynski E.A.	Angiogenesis 2020 <sup>117</sup>	The authors collected evidence linking vessel co-option with resistance to anti-angiogenic drugs in numerous tumour types. In human studies of both primary hepatocellular carcinoma and liver metastases the non-angiogenic replacement growth pattern has been described. The authors list the studies in animals and humans that associate this growth pattern with resistance to anti-VEGF and/or anti-angiogenic compounds.

Latacz E.	Angiogenesis 2020 <sup>31</sup>	The authors of this review hypothesize that common biological themes may be responsible for the HGPs of tumours in different organs, for example brain, lungs and liver. They further stress that cancer cell motility may be one of the driving forces behind the vessel co-opting (replacement) HGP.
Blazquez R.	Semin Cancer Biol 2020; 60: 324-333	Nine patterns of the macro-metastasis/organ parenchyma interface (MMPI) divided over 3 groups are described. The 3 subgroups are: 'displacing' (non-infiltrative) and two infiltrative MMPI-groups: 'epithelial' and 'diffuse'. An organ-independent MMPI assessment protocol is proposed.
Latacz E.	Semin Cancer Biol 2021 <sup>66</sup>	The authors argue that, based on the (retrospective) studies discussed in this review, we will be able to identify HGPs of liver metastases through medical imaging soon. This will significantly encourage medical oncologists to implement HGPs in clinical practice. The most promising results were achieved in studies that developed a radiomic algorithm.
Caetano Oliveira R.	Semin Cancer Biol 2021 <sup>118</sup>	This review focusses on the possibilities to identify the HGPs when a surgical liver resection specimen is not available (pre-surgery, in patients not eligible for surgical resection of their liver metastases, during systemic treatment to detect a change of HGP as a marker of response/resistance,).
Rigamonti A.	Cancers 2021 <sup>119</sup>	Parameters that predict clinical behaviour of CRC liver metastases are discussed in this review, the HGP being one of these parameters.
Kurebayashi Y.	Hepatol Res 2021 <sup>78</sup>	The immune microenvironment of hepatocellular carcinoma, intrahepatic cholangiocarcinoma and CRC liver metastases is discussed. Although there is a clear relationship between immune cell infiltration and HGP, the authors conclude that the knowledge of the interaction between cancer cells in the liver, immune cells and non-immune stromal cells is still incomplete and can be expanded by single cell RNA-sequencing.

Garcia-Vicién G.	Int J Mol Sci 2021 <sup>120</sup>	Several aspects of the liver microenvironment, such as the sinusoidal vasculature, the arterial and venous blood supply, and the specific mesenchymal and immune cell component, are addressed in the context of the HGPs of CRC liver metastases. The authors conclude that we still do not know what causes one or the other HGP when cancer cells arrive in the liver and form a metastasis.
Haas G	Front Cell Dev Biol. 2021 <sup>121</sup>	Vessel co-option and the HGPs of liver metastases but also of tumours growing in other organs are discussed. The idea of the distinct metabolic status of cancer cells in the replacement HGP being a potential therapeutic target is launched in this review.
Rompianesi G	World J Gastroenterol 2022 <sup>122</sup>	Review of studies implementing artificial intelligence (machine learning and deep learning) in the diagnosis and management of patients with CRC liver metastases. The authors conclude that an accurate identification of the HGPs (by medical imaging) could significantly improve individualized treatment approaches.

Hypotheses to explain the biology of the	Supporting evidence and/or supporting argument
different HGPs of liver metastases	
Site of implantation	
The site of cancer cell implantation in the liver	In animal models of liver metastasis (where cancer cells were introduced either via an arterial
determines the HGP	route or a portal route) the arterial route gave rise to a significantly higher proportion of
	desmoplastic metastases, originating from within portal tracts, than when cancer cells entered
	the liver via the vena portae, which more often resulted in a replacement-type liver metastases
	(Paku S & Lapis K, 1993 <sup>123</sup> ; Vidal-Vanaclocha F, 2008 <sup>124</sup> ).
Revertant in situ growth	
The replacement HGP is a reversion to in situ	Cancer cells in replacement-type liver metastases take the place of hepatocytes and rest on the
growth of cancer cells (growth within the	Space of Disse. The hybrid ductular structures (cancer cell-cholangiocyte) and growth within bile
boundaries of a basement membrane)	ducts are other examples of <i>in situ</i> growth of cancer cells in the liver. Revertant <i>in situ</i> growth
	has been described in lymph node metastases of cancer which adopt a similar growth pattern
	with cancer cells replacing lymphocytes and co-opting the vasculature (Barsky SH, 1997 <sup>125</sup> ).
Coagulation and inflammation	
The presence (desmoplastic) or absence	Angiogenesis, coagulation, inflammation, and fibrosis are interrelated processes during wound
(replacement) of coagulation and inflammation	healing and may also be the driving force behind the desmoplastic HGP of liver metastases.
determine the HGPs	When cancer cells can avoid activating any of these processes, liver metastases can adopt the
	replacement HGP. Only minimal fibrin deposits and hypoxia, one of the factors inducing

	angiogenesis, occur in liver metastases with a replacement HPG (Stessels F, $2004^{38}$ ) and
	replacement pattern liver metastases often show an 'immune desert' (Stremitzer S, 2020 <sup>2</sup> ).
Response to liver injury	
The HGPs reflect the response patterns of the	There are two responses to liver injury – the fibrotic response and the liver regeneration
liver to injury, with the desmoplastic HGP	response (Ding B, 2014 <sup>82</sup> ). The desmoplastic rim contains a portal-type of stroma (this
resembling biliary liver fibrosis and the	manuscript) and proliferating bile ducts (ductular reaction) which resembles the fibrotic
replacement pattern resembling liver	response to liver injury (Schuppan D, 2013 <sup>126</sup> ). In replacement-type liver metastases, the cancer
regeneration.	cells are arranged in cell plates and replace the parenchymal hepatocytes, thereby preserving
	the vascular architecture of the liver parenchyma, which resembles morphologically progenitor
	cell-driven liver regeneration (Deszo K, 2012 <sup>127</sup> ).
Transcriptional reprogramming	
The HGPs are the result of transcriptional	CRC cells have been shown to express liver-specific genes in liver metastases, thereby loosing
reprogramming driven by an HGP-specific	expression of colon-specific genes. This reprogramming is driven by a change in enhancer-
epigenetic landscape.	regions in the genome (Teng S, 2020 $^{52}$ ). In the replacement HGP, cancer tissue mimics liver tissue
epigenetic landscape.	regions in the genome (Teng S, 2020 <sup>52</sup> ). In the replacement HGP, cancer tissue mimics liver tissue histologically, supporting the hypothesis that cancer cells switch on a liver organogenesis
epigenetic landscape.	regions in the genome (Teng S, 2020 <sup>52</sup> ). In the replacement HGP, cancer tissue mimics liver tissue histologically, supporting the hypothesis that cancer cells switch on a liver organogenesis program that may be driven by the sinusoidal endothelial cells as in vascularizing organogenesis
epigenetic landscape.	regions in the genome (Teng S, 2020 <sup>52</sup> ). In the replacement HGP, cancer tissue mimics liver tissue histologically, supporting the hypothesis that cancer cells switch on a liver organogenesis program that may be driven by the sinusoidal endothelial cells as in vascularizing organogenesis (Matsumoto K, 2001 <sup>80</sup> ; Crivellato E, 2007 <sup>81</sup> ; Ding B, 2014 <sup>82</sup> ; Daniel E, 2019 <sup>83</sup> ). Desmoplastic liver
epigenetic landscape.	regions in the genome (Teng S, 2020 <sup>52</sup> ). In the replacement HGP, cancer tissue mimics liver tissue histologically, supporting the hypothesis that cancer cells switch on a liver organogenesis program that may be driven by the sinusoidal endothelial cells as in vascularizing organogenesis (Matsumoto K, 2001 <sup>80</sup> ; Crivellato E, 2007 <sup>81</sup> ; Ding B, 2014 <sup>82</sup> ; Daniel E, 2019 <sup>83</sup> ). Desmoplastic liver metastases histologically resemble the primary colorectal tumour and may also have a similar
epigenetic landscape.	regions in the genome (Teng S, 2020 <sup>52</sup> ). In the replacement HGP, cancer tissue mimics liver tissue histologically, supporting the hypothesis that cancer cells switch on a liver organogenesis program that may be driven by the sinusoidal endothelial cells as in vascularizing organogenesis (Matsumoto K, 2001 <sup>80</sup> ; Crivellato E, 2007 <sup>81</sup> ; Ding B, 2014 <sup>82</sup> ; Daniel E, 2019 <sup>83</sup> ). Desmoplastic liver metastases histologically resemble the primary colorectal tumour and may also have a similar transcriptional profile.

The ability of cancer cells to move and migrate	Knocking down of ARPC3, a gene coding for a subunit of an actin nucleating complex necessary
determines the HGPs because cancer cell motility	for cell motility, or <i>RUNX1</i> , coding for Runt Related Transcription Factor-1 (which is upstream of
is necessary for the replacement HGP.	ARP2/3) changes the HGP from a replacement pattern to a desmoplastic pattern in an animal
	model of liver metastasis (Frentzas S, 2016 <sup>41</sup> ; Rada M, 2021 <sup>111</sup> ).
Replacement HGP is the default	
The replacement HGP is the default growth	Remnants of co-opted portal triads are present in the centre of liver metastases, independent
pattern.	of the HGP. This suggests that desmoplastic liver metastases originate from replacement-type
	metastases, given that co-option of portal triads is not observed at the interface with the liver
	in desmoplastic liver metastases. Cancer cells also replace normal epithelial cells when they
	spread within a bile duct or form hybrid structures with cholangiocytes of a ductular reaction
	(this manuscript), supporting the idea the cancer cells have a natural tendency to interact with
	normal cells. What induces the transition from replacement to desmoplastic growth is still
	unknown.
Angiotropic extravascular migration and	Both the growth along sinusoidal blood vessels via angiotropic migration and pericyte mimicry
pericyte mimicry	and the histological resemblance of replacement liver metastases to liver parenchyma suggest
The replacement HGP relies on these processes.	that programs of embryogenesis are active in this type of metastases (Lugassy C, 2020 <sup>33</sup> ).









Κ





## Figure 3







Figure 4



CK19-CK18



С

D



CK19-CK18





CK20-CK7



CK20-CK7
## Figure 5

# Α

В





Patient

PDX



Patient



PDX

## Figure 6





Figure 7



В













CK20-CK7





CD146-NGFR



CK18-SMA









CK19-CK18

Table 2.						
	Desmoplastic	Replacement	Pushing	Sinusoidal	Portal (including intrabiliar)	
General architecture	A desmoplastic rim separates metastatic tissue from liver tissue.	Cancer cell are arranged in plates in continuity with the hepatocyte plates.	Metastatic tissue pushes the liver tissue aside (without recognizable desmoplastic rim).	Cancer cells grow in the sinusoidal vessel lumina or in the Disse space, adjacent to the hepatocyte plates.	Metastatic tissue grows within portal tracts and septa and/or within the lumen of biliary branches	
Liver architecture mimicry	-	+	-	+	n.a.	
Liver stroma preserved	-	+	-	+	+	
Contact of cancer cells with liver epithelial cells	Not with hepatocytes Occasional contact with cholangiocytes of ductular reaction	+ (hepatocytes)		-	With cholangiocytes if intrabiliary growth	
Desmoplastic reaction around the metastasis	+	-	-	-	n.a.	
Compression of liver cell plates	+	-/+	+	-	n.a.	
Contour	sharp	irregular	sharp	irregular	n.a.	
Inflammatory cell infiltrate	++	+/-	+/-	+/-	n.a.	
Proliferation of bile ducts (ductular reaction)	+/-	-	-	-	-/+	
Glandular differentiation (if adenocarcinoma)	+	-	+	-	+	
	Figures 1A-C	Figures 1D-F	Figures 1G & H	Figure 1I	Figures 1J & K	

		missing (%)	n = 1931 (%)	
Cohort	Erasmus MC		903 (47)	
	MSKCC		716 (37)	
	Radboud UMC		312 (16)	
Age at resection CRLM - (median [IQR])			64.0 [56.0, 71.0]	
Gender	Male		1170 (61)	
	Female		761 (39)	
ASA classification	ASA I-II	39 (2)	1284 (68)	
	ASA >II		609 (32)	
Primary tumour location	Left-sided	62 (3)	458 (25)	
	Right-sided		798 (43)	
	Rectal		613 (33)	
T-stage	рТ 0-2	87 (5)	287 (16)	
	рТ 3-4		1557 (84)	
N-stage	NO	31 (2)	729 (38)	
	N+		1172 (62)	
Number of CRLM - (median [IQR])	12 (1)	2.0 [1.0, 3.0]		
Diameter of largest CRLM in cm - (media	35 (2)	2.8 [1.9, 4.5]		
Disease-free interval in months* - (media	an [IQR])	14 (1)	1.0 [0.0, 17.0]	
Synchronous (DFI ≤3 months)	Synchronous		1023 (53)	
	Metachronous		908 (47)	
Preoperative CEA in µg/L - (median [IQR],	)	143 (7)	11.0 [4.0, 33.7]	
Perioperative systemic chemotherapy	No chemotherapy	41 (2)	773 (41)	
	Neoadjuvant only		689 (36)	
	Adjuvant only		232 (12)	
	Perioperative		196 (10)	
Resection margin involved	No	10 (1)	1675 (87)	
	Yes		247 (13)	
Extrahepatic disease**	No		1731 (90)	
	Yes		200 (10)	

#### Table 3. Baseline characteristics

\* Between resection of primary tumour and detection of CRLM

\*\* Defined as any extrahepatic disease with the exception of the primary tumour present at the time of or prior to first CRLM surgery.

Abbreviations in alphabetical order: ASA: American Society of Anaesthesiologists; CEA: carcinoembryonic antigen; CRLM: colorectal liver metastasis; DFI: disease-free interval; Erasmus MC: Erasmus MC Cancer Institute; IQR: interquartile range; MSKCC: Memorial Sloan Kettering Cancer Center; Radboud UMC: Radboud University Medical Center.

		Overall survival (95%CI)			Disease-free survival (95%CI)				
Cut-off	n (%)	5 year - %	10 year - %	Median - <i>months</i>	Adjusted HR*	5 year - %	10 year - %	Median - months	Adjusted HR*
Entire cohort	1931 (100)	50 (47-53)	28 (26-32)	60 (56-65)	-	22 (20-24)	18 (16-21)	13 (12-13)	-
Rotterdam cut-off									
Non-desmoplastic	1516 (79)	45 (42-48)	25 (22-28)	53 (49-58)	reference	18 (16-20)	14 (12-17)	11 (11-12)	reference
Desmoplastic	415 (21)	66 (61-72)	42 (35-50)	88 (77-112)	0.64 (0.52-0.78)	38 (33-43)	33 (28-39)	24 (20-33)	0.61 (0.52-0.71)
Rotterdam cut-off - discrete									
100% non-desmoplastic	201 (10)	48 (41-56)	21 (14-31)	57 (44-69)	reference	20 (15-27)	15 (10-23)	12 (10-15)	reference
67.1-99.9% non-desmoplastic	549 (28)	41 (36-46)	22 (18-28)	48 (44-55)	1.13 (0.89-1.45)	17 (14-21)	14 (11-18)	11 (10-12)	1.10 (0.89-1.35)
33.1-67% non-desmoplastic	305 (16)	46 (40-54)	31 (24-39)	55 (45-66)	0.95 (0.72-1.25)	19 (14-24)	16 (12-22)	11 (10-13)	0.99 (0.79-1.25)
0.1-33% non-desmoplastic	461 (24)	49 (44-55)	25 (20-32)	58 (51-70)	1.05 (0.81-1.36)	18 (14-22)	13 (9-17)	12 (11-13)	1.05 (0.85-1.31)
100% desmoplastic	415 (21)	66 (61-72)	42 (35-50)	88 (77-112)	0.67 (0.51-0.88)	38 (33-43)	33 (28-39)	24 (20-33)	0.64 (0.51-0.80)
Predominant HGP cut-off (>50%)									
Predominant replacement	839 (43)	42 (38-46)	23 (19-27)	49 (45-56)	reference	18 (16-22)	15 (12-18)	11 (10-12)	reference
Predominant pushing	19 (1)	34 (17-66)	NA	24 (17-NA)	1.03 (0.55-1.95)	6 (1-37)	NA	8 (4-19)	1.12 (0.64-1.95)
Mixed	42 (2)	47 (33-69)	25 (11-55)	53 (33-129)	1.04 (0.65-1.68)	15 (7-32)	11 (4-29)	11 (8-23)	1.23 (0.84-1.78)
Predominant desmoplastic	1031 (53)	57 (53-61)	34 (30-39)	72 (67-79)	0.76 (0.65-0.88)	26 (23-29)	22 (19-25)	14 (13-17)	0.82 (0.73-0.93)

### Table 4. Overall and disease-free survival estimates for different HGP cut-offs in 1931 patients treated with curative intent resection for CRLM

\* Multivariable regression model (n=1565 included in full-case analyses) corrected for age, gender, ASA class, primary tumour location, T-stage, nodal status, disease-free interval (continuous), number of CRLM (continuous), size of largest CRLM (continuous), preoperative CEA (continuous), extrahepatic disease, resection margin status, and perioperative systemic chemotherapy.

Abbreviations in alphabetical order: ASA: American Society of Anaesthesiologists; CEA: carcinoembryonic antigen; CRLM: colorectal liver metastasis; HGP: histopathological growth pattern; HR: hazard ratio; NA: not available.

Table 5. Standard method for histopathological growth pattern assessment of liver metastases.

- Sampling of resection specimens:
  - Complete sampling (tumour-liver interface and centre) of metastases up to 2 cm.
  - Sampling of a complete central section (tumour-liver interface and centre) of metastases larger than 2 cm.
  - If an alternative sampling method is applied, for example a tumour-type specific approach, this should be reported.
- The growth pattern is a histological parameter assessed by light microscopic imaging
  of good quality H&E sections of FFPE tissue of resection specimens of liver
  metastases. Tissue cores from needle biopsy procedures are not suitable for HGP
  assessment. Resection specimen tissue sections with only a limited part of the
  tumour-liver interface are considered insufficient to assess the growth pattern of
  liver metastases. Also, if no viable tumour tissue is present in the metastasis, the
  growth pattern cannot be assessed. Delayed fixation (autopsy cases), surgical cautery
  or radiofrequency ablation artifacts may lead to insufficient quality of the tissue
  sections for scoring the growth patterns.
- The histological growth patterns of liver metastases can be evaluated by a pathologist or by any other investigator trained by a pathologist. The authors of the guidelines may be contacted for training sessions.
- The growth pattern is a characteristic of the tumour–liver interface, more specifically the interface with the adjacent non-tumorous hepatic lobular tissue. The centre of the metastasis does not contribute to the classification of a growth pattern.
- The three common growth patterns are: desmoplastic, pushing and replacement.
- The sinusoidal growth pattern is rare. In addition, metastases can grow in portal tracts and inside biliary ducts.
- When more than one growth pattern is present in a metastasis: estimate the relative fraction of each growth pattern as a percentage of the total length of the interface\*.

- In case of multiple metastases/patient: assess the growth pattern(s) in every individual liver metastasis.
- Reporting of the HGPs per patient\*:
  - For each metastasis (defined by its largest diameter), report the proportion of the interface with replacement, desmoplastic and pushing HGP (for example: 'metastasis 1: 20% replacement, 80% desmoplastic, 0% pushing).
  - Small areas with a distinct HGP covering less than 5% of the interface should still be reported.
  - The presence of intrabiliary, portal and sinusoidal growth should be reported as a separate remark.
  - 'Escape' should be reported as being absent or present in metastases resected after chemotherapy.
- The categorisation of a patient according to the growth pattern of a liver metastasis or of multiple metastases will depend on the primary tumour type and the aim of the growth pattern assessment.
- Caveats and practical tips:
  - Portal tracts at the tumour–liver interface and growth near the liver capsule (facing the peritoneal surface or soft tissue without intermediate liver parenchyma) should not be considered as part of the tumour-liver interface.
  - Metastatic growth inside portal tracts or biliary ducts should not be regarded as desmoplastic growth.
  - The presence and extent of intrabiliary tumour growth can be underestimated, as the biliary epithelium is often replaced by cancer cells which eventually fill the lumen with accompanying necrosis.
  - Reactive proliferation of bile ducts (ductular reaction) in the desmoplastic rim can simulate a replacement growth pattern. In addition, cancer cells can build common structures with the reactive bile ductuli.
  - In case of severe inflammation and associated tissue changes it may be difficult to identify the growth patterns. The presence of co-opted hepatocytes and tumour cell-hepatocyte contact in the periphery of the metastasis are indicative of the replacement growth pattern. Immunohistochemistry or silver impregnation staining of the sections (e.g.,

Gordon- Sweet's reticulin staining) may be helpful to identify the growth patterns.

• Pushing-type of growth should not be overestimated: only when there is no cancer cell-hepatocyte contact, the pushing HGP can be considered.

#### \*Remark:

Specific scoring and reporting rules may apply to certain tumour types and settings. For example, when the HGPs are assessed to obtain prognostic information in a patient with CRLM, it will be sufficient to look for areas of replacement HGP to distinguish a non-desmoplastic from a desmoplastic status.